BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87. [PMID: 25069599 DOI: 10.1002/hep.27259] [Cited by in Crossref: 957] [Cited by in F6Publishing: 811] [Article Influence: 136.7] [Reference Citation Analysis]
Number Citing Articles
1 Panyala BR, Mukherjee RM, Devarakonda H, Tadivaka S, Padaki NR, Sharma M, Duvvuru NR. Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis. Indian J Gastroenterol 2019;38:110-6. [PMID: 30903612 DOI: 10.1007/s12664-019-00934-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hoshino K, Sugiyama M, Date T, Maruwaka S, Arakaki S, Shibata D, Maeshiro T, Hokama A, Sakugawa H, Kanto T. Phylogenetic and phylodynamic analyses of hepatitis C virus subtype 1a in Okinawa, Japan. J Viral Hepat. 2018;25:976-985. [PMID: 29577516 DOI: 10.1111/jvh.12898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ikram A, Obaid A, Awan FM, Hanif R, Naz A, Paracha RZ, Ali A, Janjua HA. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Antiviral Res 2017;137:112-24. [PMID: 27984060 DOI: 10.1016/j.antiviral.2016.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
4 Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Gastroenterology 2018;155:1120-1127.e4. [PMID: 29958855 DOI: 10.1053/j.gastro.2018.06.042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 14.7] [Reference Citation Analysis]
5 Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, Cardeñoso L, Rodriguez-Granjer J, Fernandez-Alonso M, Aguilera A, Alvarez M, Galán JC, García F. Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS One 2016;11:e0153754. [PMID: 27097040 DOI: 10.1371/journal.pone.0153754] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
6 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
7 Pybus OG, Thézé J. Hepacivirus cross-species transmission and the origins of the hepatitis C virus. Curr Opin Virol 2016;16:1-7. [PMID: 26517843 DOI: 10.1016/j.coviro.2015.10.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
8 El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12:1265-1272. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
10 O'Brien TR, Jackson SS. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection? J Interferon Cytokine Res 2019;39:618-26. [PMID: 31161939 DOI: 10.1089/jir.2019.0048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Goonawardane N, Ross-Thriepland D, Harris M. Regulation of hepatitis C virus replication via threonine phosphorylation of the NS5A protein. J Gen Virol 2018;99:62-72. [PMID: 29139348 DOI: 10.1099/jgv.0.000975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cheng H, Xu C, Zhang D, Zhang Z, Liu J, Lv X. Multiclass identification of hepatitis C based on serum Raman spectroscopy. Photodiagnosis Photodyn Ther 2020;30:101735. [PMID: 32171878 DOI: 10.1016/j.pdpdt.2020.101735] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Campbell A, Podsadecki T. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. J Hepatol 2016;64:19-28. [PMID: 26321288 DOI: 10.1016/j.jhep.2015.08.015] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
14 Ramirez S, Fernandez-Antunez C, Mikkelsen LS, Pedersen J, Li YP, Bukh J. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrob Agents Chemother 2020;64:e01888-19. [PMID: 31818814 DOI: 10.1128/AAC.01888-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
15 Zhang S, Sun F, Ren T, Duan Y, Gu H, Lai C, Wang Z, Zhang P, Wang X, Yang P. Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice. Antiviral Res 2017;145:168-74. [PMID: 28778831 DOI: 10.1016/j.antiviral.2017.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Palmer BA, Schmidt-Martin D, Dimitrova Z, Skums P, Crosbie O, Kenny-Walsh E, Fanning LJ. Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses. J Virol 2015;90:3318-29. [PMID: 26719263 DOI: 10.1128/JVI.02995-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
18 Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Thiagarajan P, Ryder SD. The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Curr Opin Infect Dis 2015;28:572-5. [PMID: 26524329 DOI: 10.1097/QCO.0000000000000204] [Reference Citation Analysis]
21 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017;152:1544-77. [PMID: 28442120 DOI: 10.1053/j.gastro.2017.03.016] [Cited by in Crossref: 135] [Cited by in F6Publishing: 114] [Article Influence: 33.8] [Reference Citation Analysis]
22 El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol 2016;9:1413-21. [PMID: 27603877 DOI: 10.1080/17512433.2016.1233813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2018;90:131-141. [PMID: 28842995 DOI: 10.1002/jmv.24921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
24 Caro-Pérez N, Martínez-Rebollar M, Gregori J, Quer J, González P, Gambato M, García-González N, González-Candelas F, Costa J, Esteban JI, Mallolas J, Forns X, Laguno M, Pérez-Del-Pulgar S. Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing. J Clin Virol 2017;92:42-7. [PMID: 28521213 DOI: 10.1016/j.jcv.2017.05.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
25 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176. [PMID: 28404132 DOI: 10.1016/s2468-1253(16)30181-9] [Cited by in Crossref: 1051] [Cited by in F6Publishing: 429] [Article Influence: 210.2] [Reference Citation Analysis]
26 Behzadi MA, Alborzi A, Kalani M, Pouladfar G, Dianatpour M, Ziyaeyan M. Immunization with a Recombinant Expression Vector Encoding NS3/NS4A of Hepatitis C Virus Genotype 3a Elicits Cell-Mediated Immune Responses in C57BL/6 Mice. Viral Immunol 2016;29:138-47. [PMID: 26909520 DOI: 10.1089/vim.2015.0085] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018;38:122-8. [DOI: 10.1089/jir.2017.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Catanese MT, Dorner M. Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology. 2015;479-480:221-233. [PMID: 25847726 DOI: 10.1016/j.virol.2015.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
29 Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019;12:626. [PMID: 31551080 DOI: 10.1186/s13104-019-4651-z] [Reference Citation Analysis]
30 Oikonomopoulou M, Demetriou VL, Kostrikis LG, Paraskevis D. Re-analysis of unassigned hepatitis C virus (HCV) strain CYHCV025: Evidence of a highly divergent lineage within genotype 1. Mol Phylogenet Evol 2017;109:362-6. [PMID: 28179183 DOI: 10.1016/j.ympev.2017.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Wang SR, Min YQ, Wang JQ, Liu CX, Fu BS, Wu F, Wu LY, Qiao ZX, Song YY, Xu GH, Wu ZG, Huang G, Peng NF, Huang R, Mao WX, Peng S, Chen YQ, Zhu Y, Tian T, Zhang XL, Zhou X. A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target. Sci Adv 2016;2:e1501535. [PMID: 27051880 DOI: 10.1126/sciadv.1501535] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 12.4] [Reference Citation Analysis]
32 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.ACS Infect Dis. 2021;7:1059-1068. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
35 Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 Zarębska-Michaluk D. Genotype 3-hepatitis C virus' last line of defense. World J Gastroenterol 2021;27:1006-21. [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Umumararungu E, Ntaganda F, Kagira J, Maina N. Prevalence of Hepatitis C Virus Infection and Its Risk Factors among Patients Attending Rwanda Military Hospital, Rwanda. Biomed Res Int. 2017;2017:5841272. [PMID: 28246598 DOI: 10.1155/2017/5841272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
38 Hemelaar J, Loganathan S, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S; WHO-UNAIDS Network for HIV Isolation and Characterization. Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015. J Virol 2020;95:e01580-20. [PMID: 33087461 DOI: 10.1128/JVI.01580-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Kivimets K, Uusküla A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis 2018;18:339. [PMID: 30031373 DOI: 10.1186/s12879-018-3242-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Owusu M, Bonney JK, Annan AA, Mawuli G, Okyere K, Mutocheluh M, Aryeequaye J, Adjei NK, Afihene M, Spangenberg K, Sylverken J, Owusu-Dabo E, Drosten C, Adu-Sarkodie Y. Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana. PLoS One 2018;13:e0203699. [PMID: 30208084 DOI: 10.1371/journal.pone.0203699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
41 McCabe L, White IR, Chau NVV, Barnes E, Pett SL, Cooke GS, Walker AS; SEARCH investigators. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials 2020;21:413. [PMID: 32423467 DOI: 10.1186/s13063-020-04350-x] [Reference Citation Analysis]
42 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
44 Mousa AM, Aldebasi YH. L-carnosine mitigates interleukin-1α-induced dry eye disease in rabbits via its antioxidant, anti-inflammatory, antiapoptotic, and antifibrotic effects. Cutan Ocul Toxicol 2021;40:241-51. [PMID: 34056995 DOI: 10.1080/15569527.2021.1935995] [Reference Citation Analysis]
45 Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Adv Ther. 2017;34:1449-1465. [PMID: 28536999 DOI: 10.1007/s12325-017-0506-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
46 Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018;16:1811-1819.e4. [PMID: 29306043 DOI: 10.1016/j.cgh.2017.12.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
47 Kong L, Jackson KN, Wilson IA, Law M. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 2015;11:148-57. [PMID: 25932568 DOI: 10.1016/j.coviro.2015.04.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
48 Romero-López C, Berzal-Herranz A. The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome. Front Microbiol 2017;8:2093. [PMID: 29163393 DOI: 10.3389/fmicb.2017.02093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
49 Keten D, Emin Ova M, Sirri Keten H, Keten A, Gulderen E, Tumer S, Caliskan A, Kulotu S. The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey. Jundishapur J Microbiol 2016;9:e31598. [PMID: 27127594 DOI: 10.5812/jjm.31598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Coppola N, De Pascalis S, Onorato L, Calò F, Sagnelli C, Sagnelli E. Hepatitis B virus and hepatitis C virus infection in healthcare workers. World J Hepatol 2016;8:273-81. [PMID: 26925201 DOI: 10.4254/wjh.v8.i5.273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
51 Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Ng M, Hayashi K, Voon P, Shulha HP, DeBeck K, Milloy MJ, Ti L. Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs. Drug Alcohol Rev 2019;38:639-43. [PMID: 31418953 DOI: 10.1111/dar.12969] [Reference Citation Analysis]
53 Zhu F, Wang Y, Xu Z, Qu H, Zhang H, Niu L, Xue H, Jing D, He H. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Mol Med Rep 2019;19:1016-23. [PMID: 30569131 DOI: 10.3892/mmr.2018.9739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther 2015;32:1117-27. [PMID: 26538232 DOI: 10.1007/s12325-015-0258-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
55 Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res 2017;148:5-14. [PMID: 29074218 DOI: 10.1016/j.antiviral.2017.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. J Med Virol 2018;90:1739-44. [PMID: 29900553 DOI: 10.1002/jmv.25243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803-1809. [PMID: 28220512 DOI: 10.1002/hep.29130] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
58 Pedersen MS, Mollerup S, Nielsen LG, Jenssen H, Bukh J, Schønning K. Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle. Microbiol Resour Announc 2019;8:e01030-19. [PMID: 31624172 DOI: 10.1128/MRA.01030-19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Ohya K, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Chayama K. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. Intern Med. 2020;59:941-944. [PMID: 31813916 DOI: 10.2169/internalmedicine.3824-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Carnero E, Fortes P. HCV infection, IFN response and the coding and non-coding host cell genome. Virus Res 2016;212:85-102. [PMID: 26454190 DOI: 10.1016/j.virusres.2015.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
61 Morales-Arraez D, Alonso-Larruga A, Diaz-Flores F, García Dopico JA, de Vera A, Quintero E, Hernández-Guerra M. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat 2019;26:1117-23. [PMID: 31077515 DOI: 10.1111/jvh.13122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
62 Barnes DM, Shekhar S, Dunn TB, Barkalow JH, Chan VS, Franczyk TS, Haight AR, Hengeveld JE, Kolaczkowski L, Kotecki BJ, Liang G, Marek JC, McLaughlin MA, Montavon DK, Napier JJ. Discovery and Development of Metal-Catalyzed Coupling Reactions in the Synthesis of Dasabuvir, an HCV-Polymerase Inhibitor. J Org Chem 2019;84:4873-92. [PMID: 30629443 DOI: 10.1021/acs.joc.8b02690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
63 Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci 2018;34:684-8. [PMID: 30527202 DOI: 10.1016/j.kjms.2018.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
64 Barathan M, Mohamed R, Yong YK, Kannan M, Vadivelu J, Saeidi A, Larsson M, Shankar EM. Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells 2018;7:E165. [PMID: 30322028 DOI: 10.3390/cells7100165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
65 Ekstrom V, Kumar R, Zhao Y, Yee ML, Sung C, Toh D, Loh PY, Tan J, Teo EK, Chow WC. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Gastroenterol Rep (Oxf) 2017;5:208-12. [PMID: 28852525 DOI: 10.1093/gastro/gow033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Naseem S, Manzoor S, Javed A, Abbas S. Interleukin-6 Rescues Lymphocyte from Apoptosis and Exhaustion Induced by Chronic Hepatitis C Virus Infection. Viral Immunol 2018;31:624-31. [PMID: 30222516 DOI: 10.1089/vim.2018.0045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
67 Gonzalez-miro M, Chen S, Gonzaga ZJ, Evert B, Wibowo D, Rehm BHA. Polyester as Antigen Carrier toward Particulate Vaccines. Biomacromolecules 2019;20:3213-32. [DOI: 10.1021/acs.biomac.9b00509] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
68 Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC. Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. Hepatology 2019;69:1426-41. [PMID: 30387174 DOI: 10.1002/hep.30342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
69 Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
70 Saha B, Kodys K, Szabo G. Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-β. Cell Mol Gastroenterol Hepatol 2016;2:302-316.e8. [PMID: 28090562 DOI: 10.1016/j.jcmgh.2015.12.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
71 Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Reference Citation Analysis]
72 Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J, Lee K, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 2016;36:635-43. [DOI: 10.1089/jir.2015.0173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
73 Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12. [PMID: 28710853 DOI: 10.1002/jmv.24903] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
74 Xiao S, Tian Z, Wang Y, Si L, Zhang L, Zhou D. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med Res Rev 2018;38:951-76. [PMID: 29350407 DOI: 10.1002/med.21484] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 20.7] [Reference Citation Analysis]
75 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
76 Yang L, Jiang C, Hu S, Diao Q, Li J, Si W, Chen M, Zhao RY. Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China. Int J Mol Sci 2016;17:403. [PMID: 26999127 DOI: 10.3390/ijms17030403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
78 He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46:711-721. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
79 El-baky NA, Uversky VN, Redwan EM. Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder. Cytokine & Growth Factor Reviews 2015;26:637-45. [DOI: 10.1016/j.cytogfr.2015.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Cooke GS, Hill AM. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy. J Viral Hepat 2015;22:459-60. [PMID: 25727262 DOI: 10.1111/jvh.12401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
81 Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2016;14:1821-1830.e6. [DOI: 10.1016/j.cgh.2016.07.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
82 Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
83 Ferreira PM, Guimarães RA, Souza CM, Guimarães LC, Barros CV, Caetano KA, Rezza G, Spadoni L, Brunini SM. Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study. BMC Public Health 2017;17:90. [PMID: 28100196 DOI: 10.1186/s12889-016-3952-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
84 Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-29. [PMID: 26694454 DOI: 10.3390/v7122968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
85 Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Janiak M, Caraballo Cortes K, Demkow U, Radkowski M. Spontaneous Elimination of Hepatitis C Virus Infection. Adv Exp Med Biol 2018;1039:45-54. [PMID: 29164488 DOI: 10.1007/5584_2017_76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
87 Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017;12:e0175525. [PMID: 28406947 DOI: 10.1371/journal.pone.0175525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
88 Fukuhara T, Yamamoto S, Ono C, Nakamura S, Motooka D, Mori H, Kurihara T, Sato A, Tamura T, Motomura T, Okamoto T, Imamura M, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y, Chayama K, Matsuura Y. Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity. Sci Rep 2017;7:45228. [PMID: 28327559 DOI: 10.1038/srep45228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Castelo A, Mello CEB, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, Silva GF, Álvares-DA-Silva MR, Zambrini H, Ferreira PRA. HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE. Arq Gastroenterol 2018;55:329-37. [PMID: 30785514 DOI: 10.1590/S0004-2803.201800000-74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
90 Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydoğdu Ö, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turk J Gastroenterol 2018;29:464-72. [PMID: 30249562 DOI: 10.5152/tjg.2018.16597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
91 Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263-271. [PMID: 28412293 DOI: 10.1016/j.jhep.2017.03.039] [Cited by in Crossref: 213] [Cited by in F6Publishing: 182] [Article Influence: 53.3] [Reference Citation Analysis]
92 Ling J, Persson Vinnersten T, Hesson JC, Bohlin J, Roligheten E, Holmes EC, Pettersson JH. Identification of hepatitis C virus in the common bed bug - a potential, but uncommon route for HCV infection? Emerg Microbes Infect 2020;9:1429-31. [PMID: 32525459 DOI: 10.1080/22221751.2020.1780950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
93 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’rear JJ, Harrington PR. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017;152:586-97. [DOI: 10.1053/j.gastro.2016.10.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
95 Robinson MW, Aranday-Cortes E, Gatherer D, Swann R, Liefhebber JM, Filipe Ada S, Sigruener A, Barclay ST, Mills PR, Patel AH. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int. 2015;35:2256-2264. [PMID: 25800823 DOI: 10.1111/liv.12830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
96 Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus 2016;5:1557. [PMID: 27652130 DOI: 10.1186/s40064-016-3224-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
97 Manee N, Thongbaiphet N, Pasomsub E, Chantratita W. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay. J Virol Methods 2017;249:31-7. [PMID: 28851606 DOI: 10.1016/j.jviromet.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
98 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Fourati S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. Viruses 2015;7:6346-59. [PMID: 26690198 DOI: 10.3390/v7122941] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
100 Yamamoto C, Nagashima S, Chuon C, Ko K, Huy Do S, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020;12:E551. [PMID: 32429467 DOI: 10.3390/v12050551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Calleja JL, Crespo J, Rincón D, Ruiz-antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-samaniego J, Sacristán B, García-eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology 2017;66:1138-48. [DOI: 10.1016/j.jhep.2017.01.028] [Cited by in Crossref: 113] [Cited by in F6Publishing: 100] [Article Influence: 28.3] [Reference Citation Analysis]
102 Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016;36:971-6. [PMID: 26786792 DOI: 10.1111/liv.13069] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
103 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
104 Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med 2016;165:345-55. [PMID: 27322622 DOI: 10.7326/M16-0065] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 18.8] [Reference Citation Analysis]
105 Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. J Viral Hepat 2018;25:144-51. [PMID: 28984012 DOI: 10.1111/jvh.12800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
106 Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother 2020;121:109657. [PMID: 31810127 DOI: 10.1016/j.biopha.2019.109657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, Page KA. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat 2017;24:117-27. [PMID: 27790803 DOI: 10.1111/jvh.12628] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
108 Boyd SD, Tracy L, Komatsu TE, Harrington PR, Viswanathan P, Murray J, Sherwat A. US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection. Clin Drug Investig 2017;37:317-26. [PMID: 28102520 DOI: 10.1007/s40261-017-0492-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
109 Afsheen Z, Ahmad B, Bashir S. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virol J 2017;14:195. [PMID: 29017555 DOI: 10.1186/s12985-017-0861-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
111 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015;7:1377-1389. [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
112 Xu H, Yu G, Sun H, Lv J, Wang M, Kong F, Zhang M, Chi X, Wang X, Wu R, Gao X, Zhong J, Sun B, Jiang J, Pan Y, Niu J. Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China. BMC Public Health 2015;15:928. [PMID: 26386815 DOI: 10.1186/s12889-015-2299-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
113 Loarec A, Carnimeo V, Molfino L, Kizito W, Muyindike W, Andrieux-Meyer I, Balkan S, Nzomukunda Y, Mwanga-Amumpaire J, Ousley J, Bygrave H, Maman D. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. AIDS 2019;33:353-5. [PMID: 30475267 DOI: 10.1097/QAD.0000000000002070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
114 Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci 2019;29:945-56. [PMID: 30700963 DOI: 10.4314/ejhs.v29i1.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
115 Batista MN, Sanches PRDS, Carneiro BM, Braga ACS, Campos GRF, Cilli EM, Rahal P. GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals. Sci Rep 2018;8:14329. [PMID: 30254334 DOI: 10.1038/s41598-018-32176-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infect Drug Resist 2018;11:2117-27. [PMID: 30464554 DOI: 10.2147/IDR.S179158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
117 Toyokuni S, Ito F, Yamashita K, Okazaki Y, Akatsuka S. Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radic Biol Med. 2017;108:610-626. [PMID: 28433662 DOI: 10.1016/j.freeradbiomed.2017.04.024] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 21.5] [Reference Citation Analysis]
118 Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2017;2:494-500. [DOI: 10.1016/s2468-1253(17)30071-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 8.8] [Reference Citation Analysis]
119 Puoti M, Rossotti R, Baiguera C, Orso M. Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? Liver Int 2016;36:181-4. [DOI: 10.1111/liv.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
120 Rangel JB, Thuler LCS, Pinto JFDC. Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol 2018;87:138-43. [PMID: 30527229 DOI: 10.1016/j.oraloncology.2018.10.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
121 Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis 2016;16:163. [PMID: 27090517 DOI: 10.1186/s12879-016-1488-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
122 Mhalla S, Hammoud R, Frih A, Kadri Y, El Argoubi A, Elmay M, Mastouri M. Prevalence and risk factors of hepatitis B and C among hemodialysis patients in Tunisia. Med Mal Infect 2018;48:175-9. [PMID: 29249466 DOI: 10.1016/j.medmal.2017.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Mol Biosyst 2016;12:3666-73. [PMID: 27731877 DOI: 10.1039/c6mb00610h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
124 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
125 Behairy BE, El-araby HA, El-guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. The Journal of Pediatrics 2020;219:106-10. [DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
126 Corcorran MA, Scott JD. Treatment of DAA-Experienced Patients with Chronic Hepatitis C. Curr Hepatology Rep 2018;17:121-9. [DOI: 10.1007/s11901-018-0395-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
127 Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, Aizaki H, Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T. Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. J Gen Virol 2020;101:188-97. [PMID: 31859613 DOI: 10.1099/jgv.0.001378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387-400. [PMID: 26055245 DOI: 10.1038/nrgastro.2015.94] [Cited by in Crossref: 270] [Cited by in F6Publishing: 241] [Article Influence: 45.0] [Reference Citation Analysis]
129 Dikopoulos N, Backhus J, Dollinger M. [The news in hepatitis C therapy]. MMW Fortschr Med 2017;159:43-52. [PMID: 29086258 DOI: 10.1007/s15006-017-9595-4] [Reference Citation Analysis]
130 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
131 Montazerhodjat V, Weinstock DM, Lo AW. Buying cures versus renting health: Financing health care with consumer loans. Sci Transl Med 2016;8:327ps6. [PMID: 26912902 DOI: 10.1126/scitranslmed.aad6913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
132 Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, Aizaki H, Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R. Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Sci Rep 2016;6:28688. [PMID: 27345289 DOI: 10.1038/srep28688] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-silberstein F. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother 2016;71:739-50. [DOI: 10.1093/jac/dkv403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
134 ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Reference Citation Analysis]
135 Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Int J Drug Policy 2017;47:144-52. [PMID: 28652072 DOI: 10.1016/j.drugpo.2017.05.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
136 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol 2016;13:11-35. [PMID: 25544499 DOI: 10.1038/cmi.2014.127] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 8.7] [Reference Citation Analysis]
137 Wedemeyer H. Towards interferon-free treatment for all HCV genotypes. Lancet 2015;385:2443-5. [PMID: 25837828 DOI: 10.1016/S0140-6736(15)60605-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
138 Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Zhang Y, El-Far M, Dupuy FP, Abdel-Hakeem MS, He Z, Procopio FA, Shi Y, Haddad EK, Ancuta P, Sekaly RP. HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. Sci Rep. 2016;6:29447. [PMID: 27385120 DOI: 10.1038/srep29447] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
140 Sehgal M, Zeremski M, Talal AH, Khan ZK, Capocasale R, Philip R, Jain P. Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. J Clin Cell Immunol. 2014;5. [PMID: 25705565 DOI: 10.4172/2155-9899.1000271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
141 Sridhar S, Yip CCY, Chan JFW, To KKW, Cheng VCC, Yuen KY. Impact of inter-genotypic recombination and probe cross-reactivity on the performance of the Abbott RealTime HCV Genotype II assay for hepatitis C genotyping. Diagn Microbiol Infect Dis 2018;91:34-7. [PMID: 29434000 DOI: 10.1016/j.diagmicrobio.2017.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
142 Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12:284-292. [PMID: 25895822 DOI: 10.1038/nrgastro.2015.53] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
143 Yu ML, Chuang WL. New treatments for HCV: Perspective from Asia. Clin Liver Dis. 2015;5:17-21. [PMID: 31312438 DOI: 10.1002/cld.442] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
144 Fan Z, Zhang Q, Chen H, He P, Li Y, Si M, Jiao X. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. Microb Pathog 2017;112:320-6. [PMID: 28993299 DOI: 10.1016/j.micpath.2017.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
145 Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, Svarovskaia E, Brainard DM, Salupere R, Orlova-Morozova E, Zhdanov K. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clin Drug Investig 2018;38:239-47. [PMID: 29177645 DOI: 10.1007/s40261-017-0606-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
146 von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 2018;36:313-21. [PMID: 29203182 DOI: 10.1016/j.vaccine.2017.10.079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
147 Maddur H, Flamm SL. Hepatitis C Genotype 3 Infection. Clinics in Liver Disease 2017;21:645-57. [DOI: 10.1016/j.cld.2017.06.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
149 Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. J Clin Pharmacol 2020;60:331-9. [PMID: 31515816 DOI: 10.1002/jcph.1524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
151 Cannalire R, Barreca ML, Manfroni G, Cecchetti V. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. J Med Chem 2016;59:16-41. [PMID: 26241789 DOI: 10.1021/acs.jmedchem.5b00825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
152 Chemaitelly H, Mahmud S, Rahmani AM, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. Int J Infect Dis 2015;40:54-63. [PMID: 26417880 DOI: 10.1016/j.ijid.2015.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
153 Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ 2017;20:740-8. [PMID: 28489467 DOI: 10.1080/13696998.2017.1325744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
154 Kerkerian G, Alimohammadi A, Raycraft T, Conway B. Repeated spontaneous clearance of hepatitis C virus infection in the setting of long-term non-progression of HIV infection. Infect Dis Rep 2017;9:7142. [PMID: 29071045 DOI: 10.4081/idr.2017.7142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
156 Asselah T, Bourlière M. Hepatitis C Virus. Gastroenterology Clinics of North America 2015;44:859-70. [DOI: 10.1016/j.gtc.2015.07.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
157 Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67:1010-1017. [PMID: 29566246 DOI: 10.1093/cid/ciy220] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 36.5] [Reference Citation Analysis]
158 Vine LJ, Sieberhagen C, Cramp ME. Diagnosis and management of hepatitis C. Br J Hosp Med (Lond) 2015;76:625-30. [PMID: 26551491 DOI: 10.12968/hmed.2015.76.11.625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
159 Bull RA, Eltahla AA, Rodrigo C, Koekkoek SM, Walker M, Pirozyan MR, Betz-Stablein B, Toepfer A, Laird M, Oh S, Heiner C, Maher L, Schinkel J, Lloyd AR, Luciani F. A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics. 2016;17:247. [PMID: 26988550 DOI: 10.1186/s12864-016-2575-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
160 Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, Mchutchison JG, Mo H, Svarovskaia E, Shafran SD. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases 2018;218:1722-9. [DOI: 10.1093/infdis/jiy401] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 32.7] [Reference Citation Analysis]
161 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Bartolini B, Lionetti R, Giombini E, Sias C, Taibi C, Montalbano M, D'Offizi G, McPhee F, Hughes EA, Zhou N, Ippolito G, Garbuglia AR, Capobianchi MR. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing. J Clin Virol 2015;66:38-43. [PMID: 25866334 DOI: 10.1016/j.jcv.2015.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
163 Woode ME, Abu-Zaineh M, Perriëns J, Renaud F, Wiktor S, Moatti JP. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat. 2016;23:522-534. [PMID: 26924428 DOI: 10.1111/jvh.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
164 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
165 Eslam M, George J. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatol Int. 2015;9:5-8. [PMID: 25788373 DOI: 10.1007/s12072-014-9600-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Leila ARS, Mousa MHA, Frakolaki E, Vassilaki N, Bartenschlager R, Zoidis G, Abdel-Halim M, Abadi AH. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds. ACS Omega 2019;4:11440-54. [PMID: 31460249 DOI: 10.1021/acsomega.9b01242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Wu Q, Li Z, Liu Q. Treatment with PTEN-Long protein inhibits hepatitis C virus replication. Virology 2017;511:1-8. [PMID: 28783500 DOI: 10.1016/j.virol.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
168 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
169 Manomaivat T, Pongsiriwet S, Kuansuwan C, Thosaporn W, Tachasuttirut K, Iamaroon A. Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study. J Investig Clin Dent 2018;9:e12316. [PMID: 29345111 DOI: 10.1111/jicd.12316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
170 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015;7:2543-50. [PMID: 26523206 DOI: 10.4254/wjh.v7.i24.2543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
172 Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
173 Caspi DD, Cink RD, Clyne D, Diwan M, Engstrom KM, Grieme T, Mei J, Miller RW, Mitchell C, Napolitano JG, Nere N, Ravn MM, Sheikh A, Wagaw S, Zhang H. Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV. Tetrahedron 2019;75:4271-86. [DOI: 10.1016/j.tet.2019.05.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
174 Quadeer AA, Louie RHY, McKay MR. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Nat Commun 2019;10:2073. [PMID: 31061402 DOI: 10.1038/s41467-019-09819-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
175 Chen M, Ma Y, Chen H, Luo H, Dai J, Song L, Yang C, Mei J, Yang L, Dong L, Jia M, Lu L. Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics. PLoS One 2015;10:e0142543. [PMID: 26562015 DOI: 10.1371/journal.pone.0142543] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
176 Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 2016;81:929-40. [PMID: 26710243 DOI: 10.1111/bcp.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
177 Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton) 2018;23:446-52. [PMID: 28339162 DOI: 10.1111/nep.13050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
178 Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol 2017;83:527-39. [PMID: 27662429 DOI: 10.1111/bcp.13138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
179 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 9.8] [Reference Citation Analysis]
180 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
181 Mokhtari C, Ebel A, Reinhardt B, Merlin S, Proust S, Roque-Afonso AM. Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test. J Clin Microbiol 2016;54:296-9. [PMID: 26582834 DOI: 10.1128/JCM.02264-15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
182 Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim YS, Kruger E, Tan SC. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25:228-235. [PMID: 29053909 DOI: 10.1111/jvh.12808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
183 Hampton H, Farrington E, Ellery A, Mckenna M, Stableforth W, Hussaini H. Community hepatitis C treatment in Cornwall: a model to improve care. Gastrointestinal Nursing 2015;13:S17-21. [DOI: 10.12968/gasn.2015.13.sup5.s17] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
184 Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology 2016;63:1120-34. [PMID: 26710081 DOI: 10.1002/hep.28428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
185 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Ramdas V, Talwar R, Banerjee M, Joshi AA, Das AK, Walke DS, Borhade P, Dhayagude U, Loriya R, Gote G, Bommakanti A, Sivaram A, Agarwal G, Goswami A, Nigade P, Mehta M, Patil V, Modi D, Kumar H, Mallurwar S, Dash A, Modi F, Kuldharan S, Srivastava P, Singh M, Narasimham L, Gundu J, Sharma S, Kamboj RK, Palle VP. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem 2019;62:10563-82. [PMID: 31710479 DOI: 10.1021/acs.jmedchem.9b01562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
187 Agyeman AA, Ofori-Asenso R, Mprah A, Ashiagbor G. Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:391. [PMID: 27507267 DOI: 10.1186/s12879-016-1708-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
188 Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology 2016;65:S2-S21. [DOI: 10.1016/j.jhep.2016.07.035] [Cited by in Crossref: 117] [Cited by in F6Publishing: 105] [Article Influence: 23.4] [Reference Citation Analysis]
189 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
190 Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One. 2015;10:e0121873. [PMID: 25803848 DOI: 10.1371/journal.pone.0121873] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
191 Lunemann S, Martrus G, Hölzemer A, Chapel A, Ziegler M, Körner C, Garcia Beltran W, Carrington M, Wedemeyer H, Altfeld M. Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function. J Hepatol 2016;65:252-8. [PMID: 27057987 DOI: 10.1016/j.jhep.2016.03.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
192 Toyoda H. Direct-acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens. Health Sci Rep 2019;2:e106. [PMID: 30937390 DOI: 10.1002/hsr2.106] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Cheung TT, Yan Chiu JW, Yuen MF, Ling Lam KS, Yung Cheung BM, Feng HP, Yeh WW, Wang J, Li W, Zhao XM, Wang Z, Mu S. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. Clin Ther 2018;40:719-732.e1. [PMID: 29724498 DOI: 10.1016/j.clinthera.2018.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Bessa LM, Launay H, Dujardin M, Cantrelle FX, Lippens G, Landrieu I, Schneider R, Hanoulle X. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B. J Biol Chem 2017;292:18024-43. [PMID: 28912275 DOI: 10.1074/jbc.M117.813766] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Carman JA, Lee KK, Gardner AI, Chong SK. Hepatitis C virus infection and anaesthesia practice: A narrative review. Anaesth Intensive Care 2021;:310057X211016004. [PMID: 34378412 DOI: 10.1177/0310057X211016004] [Reference Citation Analysis]
196 Rasche A, Sander AL, Corman VM, Drexler JF. Evolutionary biology of human hepatitis viruses. J Hepatol 2019;70:501-20. [PMID: 30472320 DOI: 10.1016/j.jhep.2018.11.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
197 Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. J Virol 2019;93:e00810-19. [PMID: 31462563 DOI: 10.1128/JVI.00810-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
198 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
199 Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore) 2021;100:e26312. [PMID: 34128871 DOI: 10.1097/MD.0000000000026312] [Reference Citation Analysis]
200 Muleta D, Kainer MA, Moore-Moravian L, Wiese A, Ward J, McMaster S, Nguyen D, Forbi JC, Mixson-Hayden T, Collier M. Notes from the Field: Hepatitis C Outbreak in a Dialysis Clinic--Tennessee, 2014. MMWR Morb Mortal Wkly Rep 2016;64:1386-7. [PMID: 26720110 DOI: 10.15585/mmwr.mm6450a5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
201 Lee SS, Kim CY, Kim BR, Cha RR, Kim WS, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea. J Viral Hepat. 2019;26:459-465. [PMID: 30516858 DOI: 10.1111/jvh.13047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
202 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
203 Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
204 Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 11.3] [Reference Citation Analysis]
205 Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clin Infect Dis 2017;65:13-9. [PMID: 28535298 DOI: 10.1093/cid/cix289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
206 Rehm J, Shield KD. Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. Biomedicines 2019;7:E99. [PMID: 31847084 DOI: 10.3390/biomedicines7040099] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
207 Sagnelli E, Alessio L, Sagnelli C, Gualdieri L, Pisaturo M, Minichini C, Di Caprio G, Starace M, Onorato L, Scotto G, Macera M, Coppola N. Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. Ann Hepatol 2018;17:47-53. [PMID: 29311411 DOI: 10.5604/01.3001.0010.7534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
208 Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol. 2019;13:839-848. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
209 Chaabna K, Dashzeveg D, Shagdarsuren T, Al-Rifai RH. Prevalence and genotype distribution of hepatitis C virus in Mongolia: Systematic review and meta-analysis. Int J Infect Dis 2021;105:377-88. [PMID: 33601031 DOI: 10.1016/j.ijid.2021.02.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Zhang X, Zhu C, Wang T, Jiang H, Ren Y, Zhang Q, Wu K, Liu F, Liu Y, Wu J. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog 2017;13:e1006321. [PMID: 28394926 DOI: 10.1371/journal.ppat.1006321] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
211 Shenge JA, Odaibo GN, Olaleye DO. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. PLoS One 2019;14:e0210724. [PMID: 30726229 DOI: 10.1371/journal.pone.0210724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Warkad SD, Nimse SB, Song KS, Kim T. Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes. ACS Omega 2020;5:10794-9. [PMID: 32455199 DOI: 10.1021/acsomega.0c00386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
213 Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
214 Bailey H, Nizova N, Martsynovska V, Volokha A, Malyuta R, Cortina-Borja M, Thorne C; Ukraine European Collaborative Study in EuroCoord. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis 2016;16:755. [PMID: 27955711 DOI: 10.1186/s12879-016-2089-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
215 Saha B, Kodys K, Adejumo A, Szabo G. Circulating and Exosome-Packaged Hepatitis C Single-Stranded RNA Induce Monocyte Differentiation via TLR7/8 to Polarized Macrophages and Fibrocytes. J Immunol 2017;198:1974-84. [PMID: 28122964 DOI: 10.4049/jimmunol.1600797] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
216 Pybus OG, Tatem AJ, Lemey P. Virus evolution and transmission in an ever more connected world. Proc Biol Sci 2015;282:20142878. [PMID: 26702033 DOI: 10.1098/rspb.2014.2878] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 17.5] [Reference Citation Analysis]
217 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13:e0199760. [PMID: 29953518 DOI: 10.1371/journal.pone.0199760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
218 Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clin Pharmacokinet 2016;55:1091-101. [PMID: 27000758 DOI: 10.1007/s40262-016-0385-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Carr RM, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res 2016;340:187-92. [PMID: 26515554 DOI: 10.1016/j.yexcr.2015.10.021] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
221 Sanchez Antolin G, Testillano M, Pascasio JM, Narvaez Rodriguez I, Prieto M, Otero A, Herrero JI, Londoño M, Fernandez Vazquez I, Castells L; Spanish Society of Liver Transplantation Study Group Collaborating Group. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplant Proc 2016;48:3013-6. [PMID: 27932134 DOI: 10.1016/j.transproceed.2016.08.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Brandão R, Marcelino R, Gonçalves F, Diogo I, Carvalho A, Cabanas J, Costa I, Brogueira P, Ventura F, Miranda A, Mansinho K, Gomes P. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018;10:E223. [PMID: 29701642 DOI: 10.3390/v10050223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
223 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
224 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
225 Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312. [PMID: 26327920 DOI: 10.1177/1756283X15587481] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 12.2] [Reference Citation Analysis]
226 Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. Clin Gastroenterol Hepatol 2016;14:1035-43. [PMID: 27062903 DOI: 10.1016/j.cgh.2016.03.040] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 18.2] [Reference Citation Analysis]
227 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
228 Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017;62:387-92. [PMID: 28554119 DOI: 10.1016/j.advms.2017.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
229 Rajhi M, Haddad-Boubaker S, Chouikha A, Bourquain D, Michel J, Hammami W, Sadraoui A, Touzi H, Ghedira K, Triki H. Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS One 2021;16:e0248249. [PMID: 33705445 DOI: 10.1371/journal.pone.0248249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Rowan PJ. What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments? World J Virol 2015;4:13-6. [PMID: 25674513 DOI: 10.5501/wjv.v4.i1.13] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
231 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
232 Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018;10:807-21. [PMID: 30533182 DOI: 10.4254/wjh.v10.i11.807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
233 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
234 Kc S, Karki N, Sharma D, Khadka S, Tiwari PS. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal. Cureus 2021;13:e15932. [PMID: 34336433 DOI: 10.7759/cureus.15932] [Reference Citation Analysis]
235 Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol 2016;3:53-75. [PMID: 27741408 DOI: 10.1146/annurev-virology-100114-055104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
236 Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group. Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 2016;214:1383-9. [PMID: 27571901 DOI: 10.1093/infdis/jiw389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
237 Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-92. [PMID: 30032031 DOI: 10.1016/j.virol.2018.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
239 Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr. 2016;28:93-100. [PMID: 26709684 DOI: 10.1097/mop.0000000000000313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
240 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
241 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
242 Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
243 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Reference Citation Analysis]
244 Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Reference Citation Analysis]
245 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
246 Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
247 Di Lello FA, Farias AA, Culasso AC, Pérez PS, Pisano MB, Contigiani MS, Campos RH, Ré VE. Changing epidemiology of hepatitis C virus genotypes in the central region of Argentina. Arch Virol 2015;160:909-15. [PMID: 25762309 DOI: 10.1007/s00705-015-2390-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
248 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
249 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. Antimicrob Agents Chemother 2017;61:e00363-17. [PMID: 28416549 DOI: 10.1128/AAC.00363-17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
251 Warkad SD, Nimse SB, Song KS, Kim T. HCV Detection, Discrimination, and Genotyping Technologies. Sensors (Basel) 2018;18:E3423. [PMID: 30322029 DOI: 10.3390/s18103423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
252 Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016;22:9613-22. [PMID: 27920482 DOI: 10.3748/wjg.v22.i43.9613] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
253 Zanaga LP, Miotto N, Mendes LC, Stucchi RS, Vigani AG. Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents. Braz J Med Biol Res 2016;49:e5504. [PMID: 27783808 DOI: 10.1590/1414-431X20165504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
254 Bletsa M, Vrancken B, Gryseels S, Boonen I, Fikatas A, Li Y, Laudisoit A, Lequime S, Bryja J, Makundi R, Meheretu Y, Akaibe BD, Mbalitini SG, Van de Perre F, Van Houtte N, Těšíková J, Wollants E, Van Ranst M, Pybus OG, Drexler JF, Verheyen E, Leirs H, Gouy de Bellocq J, Lemey P. Molecular detection and genomic characterization of diverse hepaciviruses in African rodents. Virus Evol 2021;7:veab036. [PMID: 34221451 DOI: 10.1093/ve/veab036] [Reference Citation Analysis]
255 Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J Gastroenterol. 2017;23:151-166. [PMID: 28104991 DOI: 10.3748/wjg.v23.i1.151] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
256 Asante-Appiah E, Ingravallo P, McMonagle P, Bystol K, Xia E, Curry S, Qiu P, Black S, Chase R, Liu R, Lahser F. Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527040 DOI: 10.1128/AAC.01269-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H. Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda. Transfusion 2017;57:2420-32. [PMID: 28671283 DOI: 10.1111/trf.14204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
258 Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control 2017;24:1073274817729240. [PMID: 28975833 DOI: 10.1177/1073274817729240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
259 Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2:814-823. [PMID: 28802814 DOI: 10.1016/s2468-1253(17)30163-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
260 Lavie M, Dubuisson J. Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly. Biochimie 2017;141:62-9. [PMID: 28630011 DOI: 10.1016/j.biochi.2017.06.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
261 Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D. Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med 2017;10:79-91. [PMID: 28405170 DOI: 10.2147/PGPM.S125452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
262 Hassany SM, Hassan W, Abo-Alam H, Khalaf M, Nafeh AM, Nasr-Eldin E, Mostafa EF. Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed. Infect Drug Resist 2020;13:1873-80. [PMID: 32606836 DOI: 10.2147/IDR.S241948] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 24.3] [Reference Citation Analysis]
264 Chantratita W, Song KS, GunHo C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD, Kim T. 6 HCV genotyping 9G test and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus genotyping. J Virol Methods 2017;239:1-8. [PMID: 27793646 DOI: 10.1016/j.jviromet.2016.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
265 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015;7:2792-810. [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
266 Nguyen LT, Dunford L, Freitas I, Holder P, Nguyen LA, O'Gorman J, Connell J, Carr M, Hall W, De Gascun C. Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen. J Clin Microbiol 2015;53:2697-700. [PMID: 25994168 DOI: 10.1128/JCM.01062-15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
267 Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016;22:3418-31. [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
268 Momose H, Matsuoka S, Murayama A, Yamada N, Okuma K, Ikebe E, Hoshi Y, Muramatsu M, Wakita T, Toyota K, Kato T, Hamaguchi I. Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection. J Clin Virol 2018;105:97-102. [PMID: 29940422 DOI: 10.1016/j.jcv.2018.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
269 McCormick AL, Macartney MJ, Abdi-Abshir I, Labbett W, Smith C, Irish D, Webster DP, Haque T. Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5'UTR. J Clin Virol 2015;66:56-9. [PMID: 25866338 DOI: 10.1016/j.jcv.2015.03.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
270 Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016;8:E176. [PMID: 27338446 DOI: 10.3390/v8060176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
271 Tong YQ, Liu B, Liu H, Zheng HY, Gu J, Liu H, Song EJ, Song C, Li Y. Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin Microbiol Infect 2015;21:874.e9-874.e21. [PMID: 26055416 DOI: 10.1016/j.cmi.2015.05.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
272 Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). J Viral Hepat. 2018;25:118-125. [PMID: 28833938 DOI: 10.1111/jvh.12782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
273 Magri MC, Prata TV, Manchiero C, Dantas BP, Mazza CC, Tengan FM. Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. BMC Infect Dis 2017;17:235. [PMID: 28356060 DOI: 10.1186/s12879-017-2340-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
274 Chamorro-de-Vega E, Gimenez-Manzorro A, Sanjurjo M; GRUVIC Study Group. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Med Clin (Barc) 2018;151:85-6. [PMID: 29295791 DOI: 10.1016/j.medcli.2017.10.041] [Reference Citation Analysis]
275 Zheng BZ, D'Andrea SV, Hanumegowda U, Knipe JO, Mosure K, Zhuo X, Lemm JA, Liu M, Rigat KL, Wang YK, Fang H, Poronsky C, Cutrone J, Wu DR, Arunachalam PN, Balapragalathan TJ, Arumugam A, Mathur A, Meanwell NA, Gao M, Roberts SB, Kadow JF. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2017;27:3294-300. [PMID: 28633899 DOI: 10.1016/j.bmcl.2017.06.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
276 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Hézode C. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. J Viral Hepat 2017;24:92-101. [PMID: 27862695 DOI: 10.1111/jvh.12635] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
278 Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc 2018;117:54-62. [PMID: 28389143 DOI: 10.1016/j.jfma.2017.02.013] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
279 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
280 Jeong S, Lee YS, Kim K, Yoon JS, Kim S, Ha J, Kang I, Choe W. 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation. Int J Mol Sci 2021;22:6499. [PMID: 34204438 DOI: 10.3390/ijms22126499] [Reference Citation Analysis]
281 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
282 Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis 2019;19:1255-63. [PMID: 31540840 DOI: 10.1016/S1473-3099(19)30264-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
283 Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. [PMID: 28469364 DOI: 10.20524/aog.2017.0136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
284 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
285 Nguyen D, Smith D, Vaughan-jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology 2020;73:794-9. [DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
286 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
287 Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 2016;100:545-57. [PMID: 26921345 DOI: 10.1189/jlb.2A1215-561R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
288 Tarragô AM, Pereira GL, Victória FDS, Marie AMA, Victória MB. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Rev Soc Bras Med Trop 2017;50:861-3. [PMID: 29340469 DOI: 10.1590/0037-8682-0094-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
289 Botheju WSP, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:2090. [PMID: 30765844 DOI: 10.1038/s41598-019-38853-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
290 Fourati S, Rodriguez C, Soulier A, Donati F, Hamadat S, Poiteau L, Demontant V, Brillet R, Ahnou N, Gricourt G, Chevaliez S, Ahmed-Belkacem A, Pawlotsky JM. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Aliment Pharmacol Ther 2020;52:1583-91. [PMID: 32886807 DOI: 10.1111/apt.16054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
291 Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019;68:140-9. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
292 Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infect Disord Drug Targets 2020;20:43-8. [PMID: 30009715 DOI: 10.2174/1871526518666180716141806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nat Rev Gastroenterol Hepatol 2015;12:218-30. [DOI: 10.1038/nrgastro.2015.36] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
295 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
296 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
297 Riaz S, Bashir MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. Braz J Microbiol 2016;47:980-6. [PMID: 27528079 DOI: 10.1016/j.bjm.2016.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
298 Zhang X, Wang T, Dai X, Zhang Y, Jiang H, Zhang Q, Liu F, Wu K, Liu Y, Zhou H, Wu J. Golgi protein 73 facilitates the interaction of hepatitis C virus NS5A with apolipoprotein E to promote viral particle secretion. Biochem Biophys Res Commun. 2016;479:683-689. [PMID: 27697522 DOI: 10.1016/j.bbrc.2016.09.152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
299 Schwarzkopf R, Novikov D, Anoushiravani AA, Feng JE, Vigdorchik J, Schurko B, Dwyer MK, Bedair HS. The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty. Bone Joint J 2019;101-B:667-74. [PMID: 31154838 DOI: 10.1302/0301-620X.101B6.BJJ-2018-0723.R3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
300 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
301 Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
302 Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016;16:459-64. [PMID: 26803446 DOI: 10.1016/S1473-3099(15)00529-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 14.2] [Reference Citation Analysis]
303 Oluremi AS, Opaleye OO, Ogbolu DO, Alli OAT, Adeola O, Alaka O, Ogunleke OA, Ojo A, Bello MD, Enitan SS, Adediji IO, Adelakun AA, Suleiman IE. High Viral Hepatitis Infection among Pregnant Women Attending Antenatal Clinic in Adeoyo Maternity Teaching Hospital Ibadan (AMTHI) Oyo State, Nigeria. J Immunoassay Immunochem 2020;41:913-23. [PMID: 32835616 DOI: 10.1080/15321819.2020.1807358] [Reference Citation Analysis]
304 Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2017;13:483-490. [PMID: 28165830 DOI: 10.1080/17425255.2017.1292253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
305 Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int 2016;36:1125-32. [PMID: 26778412 DOI: 10.1111/liv.13067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
306 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
307 Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VW, Wong GL, Nguyen MH. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol. 2017;112:1111-1119. [PMID: 28440303 DOI: 10.1038/ajg.2017.123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
308 Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
309 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol. 2015;21:10811-10823. [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
310 Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis 2016;63 Suppl 1:S3-S11. [PMID: 27363438 DOI: 10.1093/cid/ciw219] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
311 Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E. Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel). 2016;4. [PMID: 27490575 DOI: 10.3390/vaccines4030027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
312 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
313 Luo A, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore) 2019;98:e15626. [PMID: 31096473 DOI: 10.1097/MD.0000000000015626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
314 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
315 Bhattacharjee C, Nandy SK, Das P, Mukhopadhyay A. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction. Infect Genet Evol 2019;69:48-60. [PMID: 30639544 DOI: 10.1016/j.meegid.2019.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J; TIGER team. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea. J Gastroenterol Hepatol 2016;31:912-20. [PMID: 26777137 DOI: 10.1111/jgh.13288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
317 Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-sobol H, Stamm LM, Brainard DM, Mchutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology 2016;151:893-901.e1. [DOI: 10.1053/j.gastro.2016.07.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
318 Zhang LQ, Xu XM, Li XY, Guo J, Wang HZ, Sun JY, Cai JP. Urinary 8-oxo-7,8-dihydroguanosine levels are elevated in HCV-infected patients. Nucleosides Nucleotides Nucleic Acids 2021;:1-12. [PMID: 34379042 DOI: 10.1080/15257770.2021.1961272] [Reference Citation Analysis]
319 Zignego AL, Monti M, Gragnani L. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. Acta Biomed 2018;89:321-31. [PMID: 30333452 DOI: 10.23750/abm.v89i3.7718] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
320 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017;9:1239-52. [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
321 Wahid B, Waqar M, Saleem K, Shafi F, Rehman Z, Hanif I, Ahmad HM, Wasim M, Sajjad, Wahid K, Idrees M. Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert ® technology. Future Virology 2018;13:467-74. [DOI: 10.2217/fvl-2017-0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Coyle JR, Goerge E, Kacynski K, Rodgers R, Raines P, Vail LS, Lowhim S. Hepatitis C Virus Infections Associated with Unsafe Injection Practices at a Pain Management Clinic, Michigan, 2014-2015. Pain Med 2017;18:322-9. [PMID: 28204717 DOI: 10.1093/pm/pnw157] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
323 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016;22:7824-40. [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 376] [Cited by in F6Publishing: 304] [Article Influence: 94.0] [Reference Citation Analysis]
324 Hopcraft SE, Damania B. Tumour viruses and innate immunity. Philos Trans R Soc Lond B Biol Sci 2017;372:20160267. [PMID: 28893934 DOI: 10.1098/rstb.2016.0267] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
325 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol. 2015;7:2676-2680. [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
326 El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res 2020;22:57-66. [PMID: 31956442 DOI: 10.1016/j.jare.2019.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
327 Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scand J Gastroenterol 2019;54:1172-5. [PMID: 31479286 DOI: 10.1080/00365521.2019.1643403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat 2017;24:895-9. [PMID: 28470815 DOI: 10.1111/jvh.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
329 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
330 Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34:40-48. [PMID: 30151932 DOI: 10.1111/jgh.14457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
331 Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader AG. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J 2017;14:208. [PMID: 29096662 DOI: 10.1186/s12985-017-0873-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
332 Khedhiri M, Ghedira K, Chouikha A, Touzi H, Sadraoui A, Hammemi W, Triki H. Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. Infect Genet Evol 2019;75:103944. [PMID: 31260787 DOI: 10.1016/j.meegid.2019.103944] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
334 Prakash S, Shukla S, Ramakrishna V, Jain A. Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected. J Med Virol 2018;90:1875-81. [PMID: 30085356 DOI: 10.1002/jmv.25277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
335 Esteban R, Buti M. Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp? Gastroenterology 2015;149:1326-30. [PMID: 26416329 DOI: 10.1053/j.gastro.2015.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
336 Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child. 2017;102:668-671. [PMID: 28473309 DOI: 10.1136/archdischild-2017-312708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
337 Walker MR, Li H, Teutsch S, Betz-Stablein B, Luciani F, Lloyd AR, Bull RA. Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. J Clin Microbiol 2016;54:1855-61. [PMID: 27170021 DOI: 10.1128/JCM.00287-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
338 Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress modulation in hepatitis C virus infected cells. World J Hepatol 2015;7:2880-9. [PMID: 26692473 DOI: 10.4254/wjh.v7.i29.2880] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
339 Li CW, Yang CJ, Sun HY, Tsai MS, Lin SP, Lin TY, Cheng CY, Lee YC, Huang YS, Liu CE, Lee YT, Tang HJ, Wang NC, Cheng SH, Ko WC, Hung CC; Taiwan HIV Study Group. Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One 2018;13:e0194149. [PMID: 29547628 DOI: 10.1371/journal.pone.0194149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
340 Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 2016;17:1215-23. [PMID: 27149603 DOI: 10.1080/14656566.2016.1182156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
341 Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Can J Gastroenterol Hepatol 2020;2020:8872120. [PMID: 33194875 DOI: 10.1155/2020/8872120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Cowton VM, Singer JB, Gifford RJ, Patel AH. Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Front Immunol 2018;9:1470. [PMID: 30013555 DOI: 10.3389/fimmu.2018.01470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
343 Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017;7:16017. [PMID: 29167469 DOI: 10.1038/s41598-017-15987-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
344 Bonsall D, Ansari MA, Ip C, Trebes A, Brown A, Klenerman P, Buck D, Piazza P, Barnes E, Bowden R; STOP-HCV Consortium. ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Res 2015;4:1062. [PMID: 27092241 DOI: 10.12688/f1000research.7111.1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
345 Teimoori A, Ebrahimi S, Keshtkar N, Khaghani S, Salmanzadeh S, Ghafari S. Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran. BMC Infect Dis 2019;19:389. [PMID: 31068133 DOI: 10.1186/s12879-019-4052-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
346 Miller MM. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. Am J Health Syst Pharm 2017;74:1045-52. [PMID: 28687550 DOI: 10.2146/ajhp60632] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
347 Cha RR, Lee SS, Lee CM, Ji SB, Jung HC, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study. Medicine (Baltimore) 2016;95:e2755. [PMID: 26871824 DOI: 10.1097/MD.0000000000002755] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
348 Sesmero E, Brown JA, Thorpe IF. Molecular simulations to delineate functional conformational transitions in the HCV polymerase. J Comput Chem 2017;38:1125-37. [PMID: 27859387 DOI: 10.1002/jcc.24662] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
349 Pereira FM, Almeida MDCC, Santos FLN, Carreiro RP, Galvão-Castro B, Grassi MFR. Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil. PLoS One 2020;15:e0223087. [PMID: 32692782 DOI: 10.1371/journal.pone.0223087] [Reference Citation Analysis]
350 Tatar B, Köse Ş, Ergun NC, Turken M, Onlen Y, Yılmaz Y, Akhan S. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. Rev Assoc Med Bras (1992) 2019;65:1470-5. [PMID: 31994628 DOI: 10.1590/1806-9282.65.12.1470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Chen W, Liao B, Hu F, Nie J, Lan Y, Li H, Lu R, Gao Y, Song Y, Zhao Q, Zheng Y, Tang X, Cai W. Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China. PLoS One 2016;11:e0161844. [PMID: 27603929 DOI: 10.1371/journal.pone.0161844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
352 Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52. [PMID: 27418632 DOI: 10.1136/gutjnl-2016-311609] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
353 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
354 Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10:789-798. [PMID: 27443347 DOI: 10.1007/s12072-016-9755-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
355 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
356 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24:4330-4340. [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 40] [Article Influence: 27.5] [Reference Citation Analysis]
357 Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, Rujirojindakul P, Kanjana S, Theamboonlers A, Tangkijvanich P. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One. 2015;10:e0126764. [PMID: 25962112 DOI: 10.1371/journal.pone.0126764] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
358 Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang WL, Yu ML, Tu HP, Dai CY. The association between hepatitis C virus infection and renal function. J Chin Med Assoc 2021;84:757-65. [PMID: 34074934 DOI: 10.1097/JCMA.0000000000000561] [Reference Citation Analysis]
359 Hopcraft SE, Evans MJ. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology 2015;62:1059-69. [PMID: 25820616 DOI: 10.1002/hep.27815] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
360 Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
361 Orkin C, Jeffery-Smith A, Foster GR, Tong CY. Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women? BMJ Open 2016;6:e010661. [PMID: 27231001 DOI: 10.1136/bmjopen-2015-010661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
362 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
363 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
364 Cink RD, Lukin KA, Bishop RD, Zhao G, Pelc MJ, Towne TB, Gates BD, Ravn MM, Hill DR, Ding C, Cullen SC, Mei J, Leanna MR, Henle J, Napolitano JG, Nere NK, Chen S, Sheikh A, Kallemeyn JM. Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis. Org Process Res Dev 2020;24:183-200. [DOI: 10.1021/acs.oprd.9b00469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 7.5] [Reference Citation Analysis]
365 Tzarum N, Wilson IA, Law M. The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Front Immunol 2018;9:1315. [PMID: 29951061 DOI: 10.3389/fimmu.2018.01315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
366 Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther 2017;6:423-33. [PMID: 28677020 DOI: 10.1007/s40121-017-0163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
367 Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]
368 Pollmann J, Rölle A, Hofmann M, Cerwenka A. Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections. Front Immunol 2017;8:566. [PMID: 28567042 DOI: 10.3389/fimmu.2017.00566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
369 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
370 Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. J Med Virol. 2018;90:109-119. [PMID: 28842997 DOI: 10.1002/jmv.24923] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
371 de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA, Perez RM, Soares MA, Santos AF. Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms. Biomed Res Int 2018;2018:2931486. [PMID: 29888255 DOI: 10.1155/2018/2931486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
372 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
373 Stone D, Niyonzima N, Jerome KR. Genome editing and the next generation of antiviral therapy. Hum Genet 2016;135:1071-82. [PMID: 27272125 DOI: 10.1007/s00439-016-1686-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
374 Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Gastroenterology 2016;151:973-985.e2. [DOI: 10.1053/j.gastro.2016.07.013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 11.8] [Reference Citation Analysis]
375 Abdurakhmanov E, Øie Solbak S, Danielson UH. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses 2017;9:E151. [PMID: 28621755 DOI: 10.3390/v9060151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
376 Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Front Microbiol 2018;9:2950. [PMID: 30564209 DOI: 10.3389/fmicb.2018.02950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
377 Gane EJ, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gastroenterology. 2016;151:902-909. [PMID: 27486033 DOI: 10.1053/j.gastro.2016.07.038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
378 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat. 2019;26:263-270. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
379 Keller CW, Schmidt J, Lünemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol 2017;4:422-45. [PMID: 28589170 DOI: 10.1002/acn3.419] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
380 Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
381 Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018;38:1295-331. [PMID: 29149530 DOI: 10.1002/med.21475] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
382 Gummow J, Masavuli MG, Mekonnen ZA, Li Y, Wijesundara DK, Shrestha AC, Voskoboinik I, Gowans EJ, Grubor-Bauk B. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines (Basel) 2020;8:E53. [PMID: 32013228 DOI: 10.3390/vaccines8010053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
383 Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect Dis 2019;6:ofz076. [PMID: 30949527 DOI: 10.1093/ofid/ofz076] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
384 Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505-513. [PMID: 28865152 DOI: 10.1002/hep.29510] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
385 Li H, Jiang JD, Peng ZG. MicroRNA-mediated interactions between host and hepatitis C virus. World J Gastroenterol. 2016;22:1487-1496. [PMID: 26819516 DOI: 10.3748/wjg.v22.i4.1487] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
386 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
387 Matsumoto J, San SN, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R, Sanbe R, Yanaka S, Sakaue H, Kato Y, Nakamura H, Yamada H, Ariyoshi N. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. J Hum Genet 2020;65:143-53. [PMID: 31645655 DOI: 10.1038/s10038-019-0685-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
388 Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
389 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
390 Harfouche M, Chemaitelly H, Mahmud S, Chaabna K, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. Epidemiol Infect. 2017;145:3243-3263. [PMID: 28988562 DOI: 10.1017/s0950268817002242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
391 Forni D, Cagliani R, Pontremoli C, Pozzoli U, Vertemara J, De Gioia L, Clerici M, Sironi M. Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front Microbiol 2018;9:854. [PMID: 29765366 DOI: 10.3389/fmicb.2018.00854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
392 Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect 2017;6:e95. [PMID: 29089588 DOI: 10.1038/emi.2017.77] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
393 McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol 2017;55:1550-6. [PMID: 28275079 DOI: 10.1128/JCM.02460-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
394 Mendes-Oliveira F, Bolina-Santos E, Salomon T, Miranda C, Cioffi J, Sabino E, Barbosa-Stancioli E, Moreno E, Carneiro-Proietti AB. Hepatitis C: Prevalence of serologic markers and risk factors in blood donors at a large blood centre in South-eastern Brazil (2007-2010). Transfus Apher Sci 2015;53:238-41. [PMID: 26138911 DOI: 10.1016/j.transci.2015.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
395 Lu M, Li J, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Zhou Y, Boscarino JA, Schmidt MA. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. J Viral Hepat. 2016;23:718-729. [PMID: 27028626 DOI: 10.1111/jvh.12538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
396 Sadeghi S, Davari M, Asli E, Gharibzadeh S, Vaziri F, Jamnani FR, Fateh A, Siadat SD. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin. Gene 2017;630:28-34. [PMID: 28827115 DOI: 10.1016/j.gene.2017.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
397 Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, Garlapati P, Shrestha B, Khalid M, Chakraborty S, Guss D, Sherigar J, Mansour M, Mohanty S. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol 2018;30:1200-7. [PMID: 30096090 DOI: 10.1097/MEG.0000000000001233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
398 Witteveldt J, Martin-Gans M, Simmonds P. Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. Antimicrob Agents Chemother 2016;60:2981-92. [PMID: 26953209 DOI: 10.1128/AAC.02932-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
399 Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019;10:3758-67. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
400 von Delft A, Humphreys IS, Brown A, Pfafferott K, Lucas M, Klenerman P, Lauer GM, Cox AL, Gaudieri S, Barnes E. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 2016;65:112-23. [PMID: 26092843 DOI: 10.1136/gutjnl-2014-308724] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
401 Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One 2018;13:e0193112. [PMID: 29466415 DOI: 10.1371/journal.pone.0193112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
402 Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forné M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia AC, Blasco A, López-Núñez C, Sánchez-Ruano JJ, Gea-Rodríguez F, Giráldez Á, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons V, Forns X. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int 2017;37:1823-32. [PMID: 28481460 DOI: 10.1111/liv.13470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
403 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
404 Dash S, Chava S, Aydin Y, Chandra PK, Ferraris P, Chen W, Balart LA, Wu T, Garry RF. Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses 2016;8:E150. [PMID: 27223299 DOI: 10.3390/v8050150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
405 Wu N, Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, Gao YH, Jin Q, Wei L. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl) 2020;133:253-61. [PMID: 31934936 DOI: 10.1097/CM9.0000000000000629] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
406 Cepeda JA, Solomon SS, Srikrishnan AK, Nandagopal P, Balakrishnan P, Kumar MS, Thomas DL, Sulkowski MS, Mehta SH. Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. Open Forum Infect Dis 2016;3:ofw156. [PMID: 27704012 DOI: 10.1093/ofid/ofw156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
407 Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol. 2015;21:11984-12002. [PMID: 26576087 DOI: 10.3748/wjg.v21.i42.11984] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
408 Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
409 Schuermans W, Orlent H, Desombere I, Descheemaeker P, Van Vlierberghe H, Geerts A, Verhelst X, Reynders M, Padalko E. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form. Int J Mol Sci 2016;17:E1384. [PMID: 27563879 DOI: 10.3390/ijms17091384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
410 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
411 Olmstead AD, Lee TD, Chow R, Gunadasa K, Auk B, Krajden M, Jassem AN. Development and validation of a real-time, reverse transcription PCR assay for rapid and low-cost genotyping of hepatitis C virus genotypes 1a, 1b, 2, and 3a. J Virol Methods 2017;244:17-22. [PMID: 28219761 DOI: 10.1016/j.jviromet.2017.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
412 Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497-502. [PMID: 28260862 DOI: 10.2147/dddt.s130945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
413 O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes Immun 2016;17:328-34. [PMID: 27307212 DOI: 10.1038/gene.2016.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
414 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
415 Mania A, Kaczmarek M, Kemnitz P, Mazur-Melewska K, Figlerowicz M, Sikora J, Służewski W, Żeromski J. Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C. Med Microbiol Immunol 2018;207:55-63. [PMID: 29119253 DOI: 10.1007/s00430-017-0526-x] [Reference Citation Analysis]
416 Shimizu Y, Shirasago Y, Kondoh M, Suzuki T, Wakita T, Hanada K, Yagi K, Fukasawa M. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. J Virol 2018;92:e02258-17. [PMID: 29437969 DOI: 10.1128/JVI.02258-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
417 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
418 El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15:1643-1652. [PMID: 27661100 DOI: 10.1080/14740338.2017.1240781] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
419 Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 2016;63:1455-70. [PMID: 26474390 DOI: 10.1002/hep.28294] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
420 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
421 Ploen D, Hildt E. Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol 2015;21:8492-507. [PMID: 26229393 DOI: 10.3748/wjg.v21.i28.8492] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
422 Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63:1511-1522. [PMID: 26299621 DOI: 10.1016/j.jhep.2015.08.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
423 Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;61:1127-34. [DOI: 10.1093/cid/civ438] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
424 Luxenburger H, Graß F, Baermann J, Boettler T, Marget M, Emmerich F, Panning M, Thimme R, Nitschke K, Neumann-Haefelin C. Differential virus-specific CD8+ T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4. J Viral Hepat 2018;25:779-90. [PMID: 29397015 DOI: 10.1111/jvh.12874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
425 Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36:1433-1441. [PMID: 27009831 DOI: 10.1111/liv.13128] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
426 Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort. World J Gastroenterol 2018;24:852-61. [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852] [Reference Citation Analysis]
427 Ryder S, Pett S, Cooke GS. Genotype 4 and the global challenge of hepatitis C treatment. Lancet Gastroenterol Hepatol 2016;1:3-4. [PMID: 28404109 DOI: 10.1016/S2468-1253(16)30006-1] [Reference Citation Analysis]
428 Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int 2017;37:662-8. [PMID: 27804195 DOI: 10.1111/liv.13298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
430 Lozano-sepulveda S, Bryan-marrugo O, Merino-mascorro J, Rivas-estilla AM. Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. Future Virology 2016;11:39-46. [DOI: 10.2217/fvl.15.97] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
431 Nakayama M, Kobayashi H, Fukushima K, Ishido M, Komada Y, Yoshizawa K. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int 2016;10:158-68. [PMID: 26264253 DOI: 10.1007/s12072-015-9654-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
432 Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. In: Farah CS, Balasubramaniam R, Mccullough MJ, editors. Contemporary Oral Medicine. Cham: Springer International Publishing; 2019. pp. 67-136. [DOI: 10.1007/978-3-319-72303-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
433 Zheng YX, Ma SJ, Xiong YH, Fan XG. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. J Gastroenterol Hepatol 2020;35:1477-87. [PMID: 32246857 DOI: 10.1111/jgh.15051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
434 Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
435 Castro GLC, Amoras EDGS, Araújo MSM, Conde SRSDS, Vallinoto ACR. Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. Braz J Infect Dis 2020;24:304-9. [PMID: 32735876 DOI: 10.1016/j.bjid.2020.06.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 55] [Article Influence: 19.8] [Reference Citation Analysis]
437 Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem 2019;167:245-68. [PMID: 30772607 DOI: 10.1016/j.ejmech.2019.02.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Guo Z, Black S, Hu Y, McMonagle P, Ingravallo P, Chase R, Curry S, Asante-Appiah E. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a. J Biol Chem 2017;292:6202-12. [PMID: 28228479 DOI: 10.1074/jbc.M116.772996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
439 Benkheil M, Paeshuyse J, Neyts J, Van Haele M, Roskams T, Liekens S. HCV-induced EGFR-ERK signaling promotes a pro-inflammatory and pro-angiogenic signature contributing to liver cancer pathogenesis. Biochem Pharmacol. 2018;155:305-315. [PMID: 30012461 DOI: 10.1016/j.bcp.2018.07.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
440 Said EA, Al-Reesi I, Al-Riyami M, Al-Naamani K, Al-Sinawi S, Al-Balushi MS, Koh CY, Al-Busaidi JZ, Idris MA, Al-Jabri AA. A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression. PLoS One 2016;11:e0153191. [PMID: 27065104 DOI: 10.1371/journal.pone.0153191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
441 Jacobson IM. Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis? Gastroenterology 2018;155:969-71. [PMID: 30201359 DOI: 10.1053/j.gastro.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
442 Chahal J, Gebert LFR, Gan HH, Camacho E, Gunsalus KC, MacRae IJ, Sagan SM. miR-122 and Ago interactions with the HCV genome alter the structure of the viral 5' terminus. Nucleic Acids Res. 2019;47:5307-5324. [PMID: 30941417 DOI: 10.1093/nar/gkz194] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
443 Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019;32:108-18. [PMID: 30496620 DOI: 10.1111/sdi.12759] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
444 Hashim A, Almahdi F, Albaba EA, Barkia O, Alkasam R, Almahmoud A, Nabil A, Alsulaimani A, Mosli M. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health 2020;10:178-83. [PMID: 32538035 DOI: 10.2991/jegh.k.200117.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
445 Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J 2017;14:88. [PMID: 28464951 DOI: 10.1186/s12985-017-0753-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
446 Wahid B, Waqar M, Rasool N, Rehman Z, Saeed J, Wasim M, Khan MA, Ali A, Rafique S, Sajjad, Idrees M. Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan. Infect Genet Evol 2018;66:66-71. [PMID: 30201500 DOI: 10.1016/j.meegid.2018.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Sepúlveda-Crespo D, Jiménez JL, Gómez R, De La Mata FJ, Majano PL, Muñoz-Fernández MÁ, Gastaminza P. Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. Nanomedicine 2017;13:49-58. [PMID: 27562210 DOI: 10.1016/j.nano.2016.08.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
448 Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25-35. [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
449 Nieto-Aponte L, Quer J, Ruiz-Ripa A, Tabernero D, Gonzalez C, Gregori J, Vila M, Asensio M, Garcia-Cehic D, Ruiz G, Chen Q, Ordeig L, Llorens M, Saez M, Esteban JI, Esteban R, Buti M, Pumarola T, Rodriguez-Frias F. Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. J Clin Microbiol 2017;55:504-9. [PMID: 27927921 DOI: 10.1128/JCM.01960-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
450 Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135281. [PMID: 26296200 DOI: 10.1371/journal.pone.0135281] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
451 Tong L, Yu W, Coburn CA, Meinke PT, Nair AG, Dwyer MP, Chen L, Selyutin O, Rosenblum SB, Jiang Y, Fells J, Hu B, Zhong B, Soll RM, Liu R, Agrawal S, Xia E, Zhai Y, Kong R, Ingravallo P, Nomeir A, Asante-Appiah E, Kozlowski JA. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Bioorg Med Chem Lett 2016;26:5132-7. [PMID: 27634194 DOI: 10.1016/j.bmcl.2016.07.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
452 European Paediatric HIVHCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. AIDS 2017;31:127-35. [PMID: 27898593 DOI: 10.1097/QAD.0000000000001285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Barclay ST, Cooke GS, Holtham E, Gauthier A, Schwarzbard J, Atanasov P, Irving WL; HCV Research UK. A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatol Med Policy 2016;1:2. [PMID: 30288304 DOI: 10.1186/s41124-016-0002-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
454 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
455 Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, Mcnally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology 2017;67:224-36. [DOI: 10.1016/j.jhep.2017.03.014] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 21.3] [Reference Citation Analysis]
456 Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
457 Patra T, Sasaki R, Meyer K, Ray RB, Ray R. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections. J Virol 2019;93:e00811-19. [PMID: 31243135 DOI: 10.1128/JVI.00811-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
458 Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13:652-658. [PMID: 28507583 DOI: 10.5114/aoms.2017.66022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
459 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Ahmadi-Ghezeldasht S, Badiei Z, Sima HR, Hedayati-Moghaddam MR, Habibi M, Khamooshi M, Azimi A. Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran. Middle East J Dig Dis 2018;10:35-9. [PMID: 29682246 DOI: 10.15171/mejdd.2017.88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
461 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
462 Mattar EH, Almehdar HA, Uversky VN, Redwan EM. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4. Mol Biosyst 2016;12:2785-97. [PMID: 27327492 DOI: 10.1039/c6mb00283h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
463 Nie B, Guo Y, Zhang K, Liu J, Yun S. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China. Arch Virol 2020;165:2013-20. [PMID: 32601956 DOI: 10.1007/s00705-020-04713-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Suzuki S, Mori K, Higashino A, Iwasaki Y, Yasutomi Y, Maki N, Akari H. Persistent replication of a hepatitis C virus genotype 1b-based chimeric clone carrying E1, E2 and p6 regions from GB virus B in a New World monkey. Microbiol Immunol 2016;60:26-34. [PMID: 26634303 DOI: 10.1111/1348-0421.12349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
465 Chantratita W, Song KS, Nimse SB, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Sonawane MD, Warkad SD, Kim T. 6 HCV Genotyping 9G test for HCV 1a, 1b, 2, 3, 4 and 6 (6a, 6f, 6i and 6n) with high accuracy. J Virol Methods 2017;246:95-9. [PMID: 28456667 DOI: 10.1016/j.jviromet.2017.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
466 Naga M, Amin M, Algendy D, Elbadry A, Fawzi M, Foda A, Esmat S, Sabry D, Rashed L, Gabal S, Kamal M. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response. World J Gastroenterol 2015;21:11141-51. [PMID: 26494968 DOI: 10.3748/wjg.v21.i39.11141] [Reference Citation Analysis]
467 Walter S, Rasche A, Moreira-Soto A, Pfaender S, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JMV, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys. J Virol 2017;91:e01711-16. [PMID: 27795428 DOI: 10.1128/JVI.01711-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
468 Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
469 Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
470 Breitinger U, Farag NS, Ali NKM, Breitinger HA. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. Biophys J 2016;110:2419-29. [PMID: 27276260 DOI: 10.1016/j.bpj.2016.04.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
471 Fernández-Caballero JA, Alvarez M, Chueca N, Pérez AB, García F. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. PLoS One 2017;12:e0175564. [PMID: 28410425 DOI: 10.1371/journal.pone.0175564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
472 Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
473 Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015;7:2829-33. [PMID: 26668694 DOI: 10.4254/wjh.v7.i28.2829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
474 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Reference Citation Analysis]
475 Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018; Epub ahead of print. [PMID: 29461687 DOI: 10.1111/liv.13727] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
476 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
477 Tsai FJ, Cheng CF, Chen CJ, Lin CY, Wu YF, Li TM, Chuang PH, Wu YC, Lai CH, Liu X, Tsang H, Lin TH, Liao CC, Huang SM, Li JP, Lin JC, Lin CC, Liang WM, Lin YJ. Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 2019;57:30-8. [PMID: 30668320 DOI: 10.1016/j.phymed.2018.09.237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
478 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol. 2014;Epub ahead of print. [PMID: 25544499 DOI: 10.1038/cmi.2014.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
479 Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
480 Mandoh SS, Ayman K, Elbardakheny A, Raaft H, Ibrahim AA, Alshaikh RA, Mansour FR. A cross sectional study of the risk factors of hepatitis C infection in North Egypt. Virusdisease 2021;32:22-8. [PMID: 33969153 DOI: 10.1007/s13337-020-00639-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
481 Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, Bibby D, Breuer J, Brown A, Bowden R, Bryant J, Bonsall D, Da Silva Filipe A, Hinds C, Hudson E, Klenerman P, Lythgow K, Mbisa JL, McLauchlan J, Myers R, Piazza P, Roy S, Trebes A, Sreenu VB, Witteveldt J, Barnes E, Simmonds P; STOP-HCV Consortium. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. J Clin Microbiol 2016;54:2470-84. [PMID: 27385709 DOI: 10.1128/JCM.00330-16] [Cited by in Crossref: 79] [Cited by in F6Publishing: 41] [Article Influence: 15.8] [Reference Citation Analysis]
482 Naz Z, Wahid B, Usman S, Saleem K, Rafique S, Ali A, Idrees M. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. J Interferon Cytokine Res 2018;38:255-60. [PMID: 29920131 DOI: 10.1089/jir.2017.0138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
483 Walker A, Kaiser R, Bartenschlager R, Timm J. Genotypic resistance testing of HCV - is there a clinical need? GMS Infect Dis 2016;4:Doc05. [PMID: 30671319 DOI: 10.3205/id000023] [Reference Citation Analysis]
484 Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
485 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
486 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
487 Huang QT, Hang LL, Zhong M, Gao YF, Luo ML, Yu YH. Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies. Medicine (Baltimore) 2016;95:e4777. [PMID: 27583932 DOI: 10.1097/MD.0000000000004777] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
488 Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
489 Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL Jr, Ward AB, Li S, Wilson IA, Law M. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A 2016;113:12768-73. [PMID: 27791120 DOI: 10.1073/pnas.1609780113] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
490 Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
491 Gordon SC, Trudeau S, Li J, Zhou Y, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Lu M; CHeCS investigators. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. J Clin Gastroenterol 2019;53:40-50. [PMID: 28737649 DOI: 10.1097/MCG.0000000000000872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
492 Han Y, Niu J, Wang D, Li Y. Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma. PLoS One 2016;11:e0153882. [PMID: 27115606 DOI: 10.1371/journal.pone.0153882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
493 Jiang X, Kanda T, Wu S, Nakamoto S, Nakamura M, Sasaki R, Haga Y, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation. PLoS One 2015;10:e0131973. [PMID: 26133378 DOI: 10.1371/journal.pone.0131973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
494 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
495 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
496 Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397. [PMID: 28128852 DOI: 10.1002/hep.29081] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 33.8] [Reference Citation Analysis]
497 Saludes V, Quer J, Gregori J, Bascuñana E, García-Cehic D, Esteban JI, Ausina V, Martró E. Identification of hepatitis C virus genotype 3 by a commercial assay challenged by natural polymorphisms detected in Spain from patients with diverse origins. J Clin Virol 2016;78:14-9. [PMID: 26946155 DOI: 10.1016/j.jcv.2016.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
498 Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Adv Ther 2018;35:1087-102. [DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
499 Kao CC, Yi G, Huang HC. The core of hepatitis C virus pathogenesis. Curr Opin Virol. 2016;17:66-73. [PMID: 26851516 DOI: 10.1016/j.coviro.2016.01.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
500 McGowan DC, Khamlichi MD, De Groot A, Pauwels F, Delouvroy F, Van Emelen K, Simmen K, Raboisson P. Synthesis and evaluation of novel HCV replication inhibitors. Mol Divers 2017;21:475-81. [PMID: 28293834 DOI: 10.1007/s11030-017-9733-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
501 Thézé J, Lowes S, Parker J, Pybus OG. Evolutionary and Phylogenetic Analysis of the Hepaciviruses and Pegiviruses. Genome Biol Evol 2015;7:2996-3008. [PMID: 26494702 DOI: 10.1093/gbe/evv202] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
502 Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B, Gowans EJ. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice. J Virol 2015;89:7991-8002. [PMID: 26018154 DOI: 10.1128/JVI.00803-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
503 Sanai FM, Altraif IH, Alswat K, AlZanbagi A, Babatin MA, AlMousa A, Almutairi NH, Aljawad MS, Alghamdi AS, Aljumah AA, Alalwan AM, Al-Hamoudi WK, Assiri AM, Dahlan Y, Alsahafi A, Alothmani HS, AlSaleemi MS, Mousa WA, Albenmousa A, Awny A, Albiladi H, Abdo AA, AlGhamdi H. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. J Infect 2018;76:536-42. [PMID: 29742470 DOI: 10.1016/j.jinf.2018.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
504 Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother 2017;51:44-53. [PMID: 27609942 DOI: 10.1177/1060028016668897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
505 Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, Tolmane I, Jeruma A, Radzisauskiene D, Mockiene E, Ambrozaitis A. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
506 Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, Arifuzzaman M, Razzaque MA, Alam R, Aziz S, Khatun H, Rahim A, Morshed M. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet J Rare Dis 2017;12:93. [PMID: 28521805 DOI: 10.1186/s13023-017-0643-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
507 Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, Bronowicki JP. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int 2017;37:1314-24. [PMID: 28177199 DOI: 10.1111/liv.13383] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
508 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig Liver Dis 2021:S1590-8658(21)00137-7. [PMID: 33893040 DOI: 10.1016/j.dld.2021.03.020] [Reference Citation Analysis]
509 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 247] [Article Influence: 118.4] [Reference Citation Analysis]
510 Trapani S, Rizzato L, Masiero L, Ricci A, Morabito V, Peritore D, Fiaschetti P, Del Sordo E, Cacciotti AR, Montemurro A, Nanni Costa A. Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals. Transplant Proc 2017;49:658-66. [PMID: 28457366 DOI: 10.1016/j.transproceed.2017.02.039] [Reference Citation Analysis]
511 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
512 Barman B, Bora K, Lynrah KG, Lyngdoh WV, Jamil M. Hepatitis C virus and its genotypes in chronic liver disease patients from Meghalaya, Northeast India. Indian J Med Microbiol 2018;36:376-80. [PMID: 30429390 DOI: 10.4103/ijmm.IJMM_17_371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
513 Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis 2019;19:809. [PMID: 31521121 DOI: 10.1186/s12879-019-4403-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
514 Plaz Torres MC, Lleo A, Aghemo A. Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. Lancet Gastroenterol Hepatol 2019;4:5-6. [PMID: 30527582 DOI: 10.1016/S2468-1253(18)30378-9] [Reference Citation Analysis]
515 Chahal J, Gebert LFR, Camargo C, MacRae IJ, Sagan SM. miR-122-based therapies select for three distinct resistance mechanisms based on alterations in RNA structure. Proc Natl Acad Sci U S A 2021;118:e2103671118. [PMID: 34385308 DOI: 10.1073/pnas.2103671118] [Reference Citation Analysis]
516 Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017;11:335-48. [PMID: 27840363 DOI: 10.5009/gnl15458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
517 da Costa Marques Borges LF, Zalis MG, Santoro-Lopes G, Varella RB. Hepatitis C virus genotypes in hemodialysis patients in Angola. J Med Virol 2019;91:518-21. [PMID: 30381830 DOI: 10.1002/jmv.25354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
518 Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, Lopez-Ruz MA, Jiménez-Aguilar P, Marquez M, Collado A, Gomez-Vidal A, Hernandez-Quero J, Tellez F, Fernandez-Fuertes E, Rivero A, López-Cortés LF; Group for the Study of Viral Hepatitis (HEPAVIR) of the Andalusian Society of Infectious Diseases (SAEI). Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis 2015;34:2247-55. [PMID: 26342330 DOI: 10.1007/s10096-015-2476-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
519 Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. J Med Chem 2016;59:10228-43. [PMID: 27792320 DOI: 10.1021/acs.jmedchem.6b01234] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
520 Narayanamurthy V, Jeroish ZE, Bhuvaneshwari KS, Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Anal Methods 2021;13:740-63. [PMID: 33511975 DOI: 10.1039/d0ay02045a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Hull MW, Yoshida EM, Montaner JS. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep 2016;18:22. [PMID: 27357277 DOI: 10.1007/s11908-016-0527-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
522 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
523 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
524 Nakamura H, Akagi Y, Terui T, Fujioka S, Komoda Y, Kinoshita W, Maeda K, Ukaji Y, Inaba T. Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. Bioorg Med Chem Lett 2020;30:126932. [PMID: 31952964 DOI: 10.1016/j.bmcl.2019.126932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
525 Prabdial-Sing N, Chirwa T, Thaver J, Smuts H, Vermeulen M, Suchard M, Puren AJ. Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012. J Viral Hepat 2016;23:881-8. [PMID: 27545625 DOI: 10.1111/jvh.12571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
526 Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017;42:14-23. [PMID: 28379888 DOI: 10.1097/01.NPR.0000515423.38284.28] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
527 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. WJH 2021;13:1069-78. [DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
528 Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver Int 2017;37:1304-13. [PMID: 28135777 DOI: 10.1111/liv.13376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
529 Pierce BG, Keck ZY, Foung SK. Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol 2016;20:55-63. [PMID: 27657659 DOI: 10.1016/j.coviro.2016.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
530 Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
532 Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166:637-648. [PMID: 28319996 DOI: 10.7326/m16-2575] [Cited by in Crossref: 327] [Cited by in F6Publishing: 136] [Article Influence: 81.8] [Reference Citation Analysis]
533 Budzko L, Marcinkowska-Swojak M, Jackowiak P, Kozlowski P, Figlerowicz M. Copy number variation of genes involved in the hepatitis C virus-human interactome. Sci Rep 2016;6:31340. [PMID: 27510840 DOI: 10.1038/srep31340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
534 Wong RJ, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG. Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. J Viral Hepat 2017;24:17-21. [PMID: 27677786 DOI: 10.1111/jvh.12609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
535 Mahmoudvand S, Shokri S, Azaran A, Seyedian SS, Makvandi M, Mirzaei H, Sheikhrobat SB. Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study. Ther Apher Dial 2021;25:218-24. [PMID: 32510846 DOI: 10.1111/1744-9987.13535] [Reference Citation Analysis]
536 Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70. [DOI: 10.1007/s12072-016-9748-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
537 Hu P, Wilhelm J, Gerresheim GK, Shalamova LA, Niepmann M. Lnc-ITM2C-1 and GPR55 Are Proviral Host Factors for Hepatitis C Virus. Viruses 2019;11:E549. [PMID: 31200545 DOI: 10.3390/v11060549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
538 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
539 European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 55] [Article Influence: 36.3] [Reference Citation Analysis]
540 Mansoor S, Riaz S, Kausar S, Muhammad Din S, Javed A, Sultan A, Mansoor A. Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? J Gen Virol 2016;97:2592-8. [PMID: 27498543 DOI: 10.1099/jgv.0.000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
541 Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
542 Kirdar S, Sener AG, Cengİz M, Aydin N. The prevalence of autoantibody and its relationship with genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection. APMIS 2016;124:979-84. [PMID: 27670736 DOI: 10.1111/apm.12593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
543 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Gallardo-Flores CE, Colpitts CC. Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches. Pathogens 2021;10:902. [PMID: 34358052 DOI: 10.3390/pathogens10070902] [Reference Citation Analysis]
545 Garagiola E, Ferrario L, Croce D, Menzaghi B, Quirino T, Rizzardini G, Foglia E. HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. Digestive and Liver Disease 2016;48:1200-7. [DOI: 10.1016/j.dld.2016.06.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
546 Hongjaisee S, Doungjinda N, Khamduang W, Carraway TS, Wipasa J, Debes JD, Supparatpinyo K. Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. Int J Infect Dis 2021;102:440-5. [PMID: 33130211 DOI: 10.1016/j.ijid.2020.10.082] [Reference Citation Analysis]
547 Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol 2019;18:450-5. [PMID: 31028014 DOI: 10.1016/j.aohep.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
548 Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Liu T, Wan Z, Liu J, Zhang L, Zhou Y, Lan K, Hu Y, Zhang C. A novel real-time reverse transcription-polymerase chain reaction assay with partially double-stranded linear DNA probe for sensitive detection of hepatitis C viral RNA. J Virol Methods 2016;236:132-8. [PMID: 27451264 DOI: 10.1016/j.jviromet.2016.07.015] [Reference Citation Analysis]
550 Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. J Comp Eff Res. 2015;4:593-605. [PMID: 26159375 DOI: 10.2217/cer.15.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
551 Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. J Virol 2016;90:8422-34. [PMID: 27412600 DOI: 10.1128/JVI.00404-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 4.2] [Reference Citation Analysis]
552 Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Reference Citation Analysis]
553 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
554 Ayoub HH, Chemaitelly H, Omori R, Abu-Raddad LJ. Hepatitis C virus infection spontaneous clearance: Has it been underestimated? Int J Infect Dis 2018;75:60-6. [PMID: 30031139 DOI: 10.1016/j.ijid.2018.07.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
555 Clausznitzer D, Harnisch J, Kaderali L. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals. Virus Res 2016;218:96-101. [PMID: 26409026 DOI: 10.1016/j.virusres.2015.09.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
556 Nii-Trebi NI, Brown CA, Osei YD, Ampofo WK, Nyarko AK. Core encoding sequences of Hepatitis C virus in Ghanaian blood donors are predominantly mosaics of different genotype 2 strains and cannot distinguish subtypes. BMC Infect Dis 2019;19:533. [PMID: 31208352 DOI: 10.1186/s12879-019-4155-4] [Reference Citation Analysis]
557 Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
558 Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016;10:1373-1383. [PMID: 27718758 DOI: 10.1080/17474124.2016.1246181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
559 Younossi Z, Brown A, Buti M, Fagiuoli S, Mauss S, Rosenberg W, Serfaty L, Srivastava A, Smith N, Stepanova M, Beckerman R. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016;23:217-26. [PMID: 26482680 DOI: 10.1111/jvh.12483] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
560 Yip CCY, Sridhar S, Lau JHN, Cheng AKW, Leung KH, Chen JHK, Chan KH, Cheng VCC, Yuen KY. Comparative performance of two commercial sample-to-result systems for hepatitis C virus quantitation and genotyping. Expert Rev Mol Diagn 2020;20:1253-8. [PMID: 32893699 DOI: 10.1080/14737159.2020.1820327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
561 Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. J Am Chem Soc 2016;138:11850-9. [PMID: 27512818 DOI: 10.1021/jacs.6b06454] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
562 Ul Abideen Z, Siddique S, Nasrullah I, Khan JS, Rehman S, Tong Y, Qamar R, Butt AM. A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2019;31:1103-9. [PMID: 30829691 DOI: 10.1097/MEG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
563 Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016;46:116-125. [PMID: 26996460 DOI: 10.1016/j.ijid.2016.03.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
564 Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med 2018;19:737. [PMID: 29707384 DOI: 10.4102/sajhivmed.v19i1.737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
565 El-Sayed M, Abdellatif Z, Elsharkawy A, El Kassas M, Abd Elmoniem R, Marzouk A, Fouad R, Esmat G, Abdel Alem S. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection 2020;48:913-22. [PMID: 32816249 DOI: 10.1007/s15010-020-01505-5] [Reference Citation Analysis]
566 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
567 Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis: Daclatasvir plus asunaprevir in non-HD and HD patients. Hepatol Res 2018;48:746-56. [DOI: 10.1111/hepr.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
568 Hegab DS, Sweilam MA. Cryoglobulinaemia in Egyptian Patients with Extrahepatic Cutaneous Manifestations of Chronic Hepatitis C Virus Infection. Dermatol Res Pract 2015;2015:182609. [PMID: 26839534 DOI: 10.1155/2015/182609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
569 Guo X, Zhong JY, Li JW. Hepatitis C Virus Infection and Vaccine Development. J Clin Exp Hepatol 2018;8:195-204. [PMID: 29892184 DOI: 10.1016/j.jceh.2018.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
570 Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol 2019;25:55-60. [PMID: 30117490 DOI: 10.4103/sjg.SJG_189_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
571 Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
572 Tung HD, Lee PL, Chen JJ, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Hou CY, Tsai HH, Wu LC, Lee C. Geographic variation of genotype 6 hepatitis C virus infection in an endemic area of southern Taiwan. J Formos Med Assoc 2020;119:1876-80. [PMID: 32620462 DOI: 10.1016/j.jfma.2020.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
573 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
574 Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016;64:301-7. [PMID: 26476290 DOI: 10.1016/j.jhep.2015.10.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 18.7] [Reference Citation Analysis]
575 Rid A, Johansson MA, Leung G, Valantine H, Burchard EG, Oh SS, Zimmerman C; PLOS Medicine Editors. Towards Equity in Health: Researchers Take Stock. PLoS Med 2016;13:e1002186. [PMID: 27898673 DOI: 10.1371/journal.pmed.1002186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
576 Hua R, Jiang X, Qi L, Guan S, Kuai Z, Qiao Y, Xu Y, Gong X, Shi Y, Kong W, Niu J, Zhang H, Shan Y. Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region. Immunol Res 2018;66:67-73. [PMID: 29151181 DOI: 10.1007/s12026-017-8962-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
577 Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech 2017;28:80-6. [PMID: 28058039 DOI: 10.7171/jbt.17-2801-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
578 Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505-1511. [PMID: 25534735 DOI: 10.1128/aac.04619-14] [Cited by in Crossref: 79] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
579 Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med 2015;7:11-20. [PMID: 25926761 DOI: 10.2147/HMER.S79584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
580 Nakamura H, Fujioka S, Terui T, Okuda S, Kondo K, Tamatani Y, Akagi Y, Komoda Y, Kinoshita W, Ito S, Maeda K, Ukaji Y, Inaba T. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. Bioorg Med Chem Lett 2020;30:127361. [PMID: 32738974 DOI: 10.1016/j.bmcl.2020.127361] [Reference Citation Analysis]
581 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
582 Mcewan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective: . European Journal of Gastroenterology & Hepatology 2017;29:208-14. [DOI: 10.1097/meg.0000000000000773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
583 Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect 2016;144:1634-40. [PMID: 27125573 DOI: 10.1017/S0950268815003064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
584 Karadağ Ö, Kaşifoğlu T, Özer B, Kaymakoğlu S, Kuş Y, İnanç M, Keser G, Kiraz S. Viral hepatitis screening guideline before biological drug use in rheumatic patients. Eur J Rheumatol 2016;3:25-8. [PMID: 27708965 DOI: 10.5152/eurjrheum.2015.150072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
585 Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W, Chen L, Guo S, Zhuang Y, Shi D, Chen L, Bao S, Cai W, Wang H, Zhou H, Xie Q. Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. J Med Virol. 2017;89:1973-1980. [PMID: 28671305 DOI: 10.1002/jmv.24894] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
586 Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
587 Hussein NR. The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy. Mediterr J Hematol Infect Dis 2017;9:e2017005. [PMID: 28105296 DOI: 10.4084/MJHID.2017.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
588 Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 20.0] [Reference Citation Analysis]
589 Nyan DC, Swinson KL. A method for rapid detection and genotype identification of hepatitis C virus 1-6 by one-step reverse transcription loop-mediated isothermal amplification. Int J Infect Dis 2016;43:30-6. [PMID: 26686938 DOI: 10.1016/j.ijid.2015.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
590 Breitinger U, Farag NS, Ali NKM, Ahmed M, El-Azizi MA, Breitinger HG. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels. J Gen Virol 2021;102. [PMID: 33709903 DOI: 10.1099/jgv.0.001571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49:99-106. [PMID: 30467877 DOI: 10.1111/apt.15043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
592 Zhu XB, Zhuo LY, Yue M, Liu M, Zang F, Fan HZ, Wu JJ, Xia XS, Zhang AM, Yu RB, Huang P. Genetic variants in IFIH1 and DDX58 influence hepatitis C virus clearance in Chinese Han population. J Med Virol 2019;91:1097-103. [PMID: 30633820 DOI: 10.1002/jmv.25398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert ML, Joos TO, Schneiderhan-Marra N. Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High Throughput 2017;6:E15. [PMID: 29855459 DOI: 10.3390/ht6040015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
594 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
595 Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-28. [PMID: 29696643 DOI: 10.1002/cpt.1099] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
596 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
597 McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015;75:515-524. [PMID: 25721433 DOI: 10.1007/s40265-015-0362-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
598 Kang IJ, Hsu SJ, Yang HY, Yeh TK, Lee CC, Lee YC, Tian YW, Song JS, Hsu TA, Chao YS, Yueh A, Chern JH. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. J Med Chem 2017;60:228-47. [PMID: 27966956 DOI: 10.1021/acs.jmedchem.6b00962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
599 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
600 Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clin Pharmacokinet 2017;56:1173-83. [PMID: 28066880 DOI: 10.1007/s40262-016-0504-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
601 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
602 Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F, Capuano A. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 2016;15:85-100. [DOI: 10.1080/14740338.2016.1221396] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
603 Bloom DE, Khoury A, Srinivasan V. Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India. PLoS One 2021;16:e0252764. [PMID: 34292958 DOI: 10.1371/journal.pone.0252764] [Reference Citation Analysis]
604 Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Reference Citation Analysis]
605 Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018;97:e0416. [PMID: 29642211 DOI: 10.1097/MD.0000000000010416] [Reference Citation Analysis]
606 van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology. 2015;61:1174-1182. [PMID: 25482139 DOI: 10.1002/hep.27641] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
607 Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol 2017;15:945-949.e1. [PMID: 28238958 DOI: 10.1016/j.cgh.2017.02.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
608 Chen M, Ma Y, Chen H, Dai J, Luo H, Jia M, Song Z. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China. PLoS One 2019;14:e0217010. [PMID: 31095618 DOI: 10.1371/journal.pone.0217010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
609 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
610 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 10] [Article Influence: 14.7] [Reference Citation Analysis]
611 Kantarjian HM, Paul S. Hepatitis C: When high drug prices preclude patient benefit. Cancer 2018;124:1644-6. [PMID: 29486061 DOI: 10.1002/cncr.31292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
612 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 98] [Cited by in F6Publishing: 80] [Article Influence: 32.7] [Reference Citation Analysis]
613 Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol. 2018;24:2555-2566. [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
614 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
615 Pedersen MS, Fahnøe U, Hansen TA, Pedersen AG, Jenssen H, Bukh J, Schønning K. A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus. J Clin Virol 2018;105:49-56. [PMID: 29886373 DOI: 10.1016/j.jcv.2018.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
616 Salum GM, Bader El Din NG, Ibrahim MK, Anany MA, Dawood RM, Khairy A, El Awady MK. Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-Induced Liver Fibrosis: A Potential Biomarker. J Interferon Cytokine Res 2017;37:310-6. [PMID: 28472595 DOI: 10.1089/jir.2016.0127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
617 Soh BYM, Kumar R, Ekstrom VSM, Lin CYH, Thangaraju S, Tan HH, Chan KP, Choong LHL, Teo D, Chow WC. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Med J 2019;60:34-9. [PMID: 29926111 DOI: 10.11622/smedj.2018078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
618 Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment. Intern Med 2018;57:2843-5. [PMID: 29780129 DOI: 10.2169/internalmedicine.0621-17] [Reference Citation Analysis]
619 Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. J Med Chem 2017;60:5699-716. [PMID: 28594175 DOI: 10.1021/acs.jmedchem.7b00426] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
620 Valkov I, Ivanova R, Alexiev A, Antonov K, Mateva L. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C. J Clin Diagn Res 2017;11:OC15-20. [PMID: 28969178 DOI: 10.7860/JCDR/2017/28609.10459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
621 Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS One 2020;15:e0233446. [PMID: 32433676 DOI: 10.1371/journal.pone.0233446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
622 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
623 Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421-431. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
624 Salas-villalobos T, Lozano-sepúlveda S, Rincón-sánchez A, Govea-salas M, Rivas-estilla A. Mechanisms involved in liver damage resolution after hepatitis C virus clearance. Medicina Universitaria 2017;19:100-7. [DOI: 10.1016/j.rmu.2017.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
625 Kelly L, Badhan A, Roberts GC, Mbisa JL, Harris M. Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. J Gen Virol 2017;98:2495-506. [PMID: 28984238 DOI: 10.1099/jgv.0.000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
626 Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother 2017;61:e02558-16. [PMID: 28193664 DOI: 10.1128/AAC.02558-16] [Cited by in Crossref: 89] [Cited by in F6Publishing: 37] [Article Influence: 22.3] [Reference Citation Analysis]
627 Khairy RM, Abdulghany HM, Abdel-Raheim S, Zenhom NM, Abd Elfatah AS, Abdalla NH. Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients. IUBMB Life 2018;70:1156-63. [PMID: 30253037 DOI: 10.1002/iub.1929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
628 Paraskevis D, Stylianou DC, Hezka J, Stern Z, Oikonomopoulou M, Mamais I, Kostrikis LG; Cyprus PWID Network. HCV Phylogeography of the General Population and High-Risk Groups in Cyprus Identifies the Island as a Global Sink for and Source of Infection. Sci Rep 2019;9:10077. [PMID: 31296903 DOI: 10.1038/s41598-019-46552-7] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
629 Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore) 2017;96:e6984. [PMID: 28562549 DOI: 10.1097/MD.0000000000006984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Wei B, Kang J, Kibukawa M, Chen L, Qiu P, Lahser F, Marton M, Levitan D. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus. J Mol Diagn 2016;18:643-56. [PMID: 27393904 DOI: 10.1016/j.jmoldx.2016.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
631 Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017;11:559-67. [PMID: 28317409 DOI: 10.1080/17474124.2017.1309284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
632 Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Reference Citation Analysis]
633 Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver Int 2020;40:2385-93. [PMID: 32445613 DOI: 10.1111/liv.14535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
634 Lee AS, van Driel ML, Crawford DH. The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res 2017;9:595-607. [PMID: 29042803 DOI: 10.2147/CEOR.S146280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. J Diabetes Investig 2019;10:418-28. [PMID: 30099847 DOI: 10.1111/jdi.12910] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
636 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
637 Iwamoto M, Calzia A, Dublineau A, Rouet F, Nouhin J, Yann S, Pin S, Sun C, Sann K, Dimanche C, Lastrucci C, Coulborn RM, Maman D, Dousset JP, Loarec A. Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. J Viral Hepat 2019;26:38-47. [PMID: 30199587 DOI: 10.1111/jvh.13002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
638 Zhang C, Hua R, Cui Y, Wang S, Yan H, Li D, Zhang Y, Tu Z, Hao P, Chen X, Zhong J, Niu J, Jin X. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. PLoS One 2017;12:e0171217. [PMID: 28170421 DOI: 10.1371/journal.pone.0171217] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
639 Audu RA, Okwuraiwe AP, Ige FA, Adeleye OO, Onyekwere CA, Lesi OA. Hepatitis C viral load and genotypes among Nigerian subjects with chronic infection and implication for patient management: a retrospective review of data. Pan Afr Med J 2020;37:335. [PMID: 33738023 DOI: 10.11604/pamj.2020.37.335.20299] [Reference Citation Analysis]
640 Kim K, Lee YS, Jeong S, Kim D, Chon S, Pak YK, Kim S, Ha J, Kang I, Choe W. A Small Molecule, 4-Phenylbutyric Acid, Suppresses HCV Replication via Epigenetically Induced Hepatic Hepcidin. Int J Mol Sci 2020;21:E5516. [PMID: 32752233 DOI: 10.3390/ijms21155516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
641 Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology 2018;514:134-41. [PMID: 29175627 DOI: 10.1016/j.virol.2017.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
642 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
643 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
644 Damavandi F, Wang W, Shen WZ, Cetinel S, Jordan T, Jovel J, Montemagno C, Wong GK. Enrichment of low abundance DNA/RNA by oligonucleotide-clicked iron oxide nanoparticles. Sci Rep 2021;11:13053. [PMID: 34158543 DOI: 10.1038/s41598-021-92376-9] [Reference Citation Analysis]
645 Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Ann Hepatol 2019;18:434-8. [PMID: 31023614 DOI: 10.1016/j.aohep.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
646 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol. 2016;22:1497-1512. [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
647 Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2020;12:eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
648 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
649 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
650 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015;7:3995-4046. [PMID: 26193307 DOI: 10.3390/v7072809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
652 Zhou S, Cella E, Zhou W, Kong WH, Liu MQ, Liu PL, Ciccozzi M, Salemi M, Chen X. Population dynamics of hepatitis C virus subtypes in injecting drug users on methadone maintenance treatment in China associated with economic and health reform. J Viral Hepat 2017;24:551-60. [PMID: 28092412 DOI: 10.1111/jvh.12677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
653 Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38:443-450. [PMID: 28756625 DOI: 10.1111/liv.13534] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
654 Dawood RM, Moustafa RI, Abdelhafez TH, El-Shenawy R, El-Abd Y, Bader El Din NG, Dubuisson J, El Awady MK. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect Dis 2019;19:932. [PMID: 31690267 DOI: 10.1186/s12879-019-4571-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
655 Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim SW, Byun JK, Kim MK, Lee S, Shin EC, Lee IK, Kang YN, Park KG. Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. Sci Rep 2016;6:30846. [PMID: 27471054 DOI: 10.1038/srep30846] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
656 Ali NK, Mohamed RR, Saleh BE, Alkady MM, Farag ES. Occult hepatitis C virus infection among haemodialysis patients. Arab J Gastroenterol. 2018;19:101-105. [PMID: 30245116 DOI: 10.1016/j.ajg.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
657 Rajhi M, Ghedira K, Chouikha A, Djebbi A, Cheikh I, Ben Yahia A, Sadraoui A, Hammami W, Azouz M, Ben Mami N, Triki H. Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa. PLoS One 2016;11:e0153761. [PMID: 27100294 DOI: 10.1371/journal.pone.0153761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
658 Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 2018;19:413-9. [PMID: 29465262 DOI: 10.1080/14656566.2018.1444030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
659 Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70. [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043] [Cited by in Crossref: 170] [Cited by in F6Publishing: 144] [Article Influence: 28.3] [Reference Citation Analysis]
660 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives. World J Gastroenterol 2021;27:4018-44. [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Reference Citation Analysis]
661 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015;7:725-37. [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
662 Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:901-10. [PMID: 30058394 DOI: 10.1080/17425255.2018.1506765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [